

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 0 737 745 A1**

(12)

**EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

(43) Date of publication:  
16.10.1996 Bulletin 1996/42

(51) Int. Cl.<sup>6</sup>: **C12N 9/10**, C12N 15/54

(21) Application number: **95903933.0**

(86) International application number:  
PCT/JP94/02182

(22) Date of filing: **22.12.1994**

(87) International publication number:  
WO 95/18217 (06.07.1995 Gazette 1995/29)

(84) Designated Contracting States:  
CH DE FR GB LI

(30) Priority: 24.12.1993 JP 348260/93  
28.03.1994 JP 57369/94  
28.04.1994 JP 91507/94

(71) Applicant: **THE INSTITUTE OF PHYSICAL &  
CHEMICAL RESEARCH**  
Wako-shi Saitama 351-01 (JP)

(72) Inventors:  
• TSUJI, Shuichi  
The Institute of Physical and  
Saitama 351-01 (JP)  
• KUROSAWA, Nobuyuki  
The Institute of Physical  
Saitama 351-01 (JP)

- HAMAMOTO, Toshiro  
The Institute of Physical  
Saitama 351-01 (JP)
- LEE, Young-Choon  
The Institute of Physical  
Saitama 351-01 (JP)
- NAKAOKA, Takashi  
The Institute of Physical  
Saitama 351-01 (JP)
- KOJIMA, Naoya  
The Institute of Physical  
Saitama 351-01 (JP)

(74) Representative: Godemeyer, Thomas, Dr.  
Hauptstrasse 58  
51491 Overath (DE)

(54) **NOVEL SUGAR-CHAIN SYNTHETASE AND PROCESS FOR PRODUCING THE SAME**

(57) Novel GalNAc $\alpha$ 2,6-sialyltransferases P-B1 and P-B3; GalNAc $\alpha$ 2,6-sialyltransferase genes encoding the above GalNAc $\alpha$ 2,6-sialyltransferases P-B1 and P-B3; and an extracellularly releasable protein catalyzing GalNAc $\alpha$ 2,6-sialic acid transfer which comprises a polypeptide portion as being an active domain of the GalNAc $\alpha$ 2,6-sialyltransferase P-B1 or P-B3 together with a signal peptide are provided. Also provided is a process for preparing a sialyltransferases which enables efficient recovery of a sialyltransferase expressed in a large quantity in microorganisms.

EP 0 737 745 A1

## Description

## Technical Field

5 The present invention relates to a sugar-chain synthetase and a DNA encoding the enzyme. More specifically, the present invention relates to an N-acetylgalactosamine $\alpha$ 2,6-sialyltransferase (GalNAc $\alpha$ 2,6-sialyltransferase) and a DNA encoding the enzyme. The enzyme is useful as medicaments having inhibitory activities against tumor metastases and viral infection, and as agents for introducing a sialic acid moieties into drugs to increase their biological activity.

10 The present invention further relates to a process for producing the sugar-chain synthetase. More specifically, the present invention relates to a process for expressing sialyltransferases in microorganisms to obtain the sialyltransferases in large quantities.

## Background Art

15 Sialic acids play an important role in a variety of biological processes, like cell-cell communication, cell-substrate interaction, adhesion. It has been known that various kinds of distinguishable cell surface sialic acids exist which change in a regulated manner during development, differentiation, and oncogenic transformation.

Sialic acids occur at the terminal positions of the carbohydrate groups of glycoproteins and glycolipids, and they are enzymatically introduced from CMP-Sia to these positions in a post translational process. For example, three linkage patterns, Sia $\alpha$ 2,6Gal, Sia $\alpha$ 2,3Gal and Sia $\alpha$ 2,6GalNAc are commonly found in glycoproteins (Hakomori, S., *Ann. Rev. Biochem.*, 50, pp.733-764, 1981), and two, Sia $\alpha$ 2,3Gal and Sia $\alpha$ 2,8Sia, occur frequently in gangliosides (Fishman, P., and Brady, R.O., *Science*, 194, pp.906-915, 1976).

The enzymes responsible for such enzymatic introduction of sialic acid (sialic acid transfer) as mentioned above are glycosyltransferases called sialyltransferases. It has been known that at least 12 different sialyltransferases are required to synthesize all known sialyloligosaccharide structures (Broquet, P. et al., *Int. J. Biochem.*, 23, 385-389, 1991; and Weinstein, J. et al., *J. Biol. Chem.*, 262, 17735-17743, 1987). Among these enzymes, five sialyltransferases have been purified so far, and it has been known that they exhibit strict specificity for acceptor substrate (Sadler, J. et al., *J. Bio. Chem.*, 254, pp.4434-4443, 1979; Weinstein, J. et al., *J. Biol. Chem.*, 257, pp.13835-13844, 1982; Rearick, J. et al., *J. Biol. Chem.*, 254, pp.4444-4451, 1979; and Joqiasse, D.H. et al., *J. Biol. Chem.*, 260, 4941-4951, 1985).

As for cDNAs encoding the aforementioned sialyltransferases, cDNAs encoding Gal $\beta$ 1,4GlcNAc $\alpha$ 2,6-sialyltransferase (Gal $\beta$ 4GlcNAc- $\alpha$ 6ST) have been cloned from various organs including liver (Weinstein, J. et al., *J. Biol. Chem.*, 262, pp.17735-17743, 1987; Grundmann U. et al., *Nucleic Acids Res.* 18, 667, 1990; Bast, B. et al., *J. Cell. Biol.*, 116, pp.423-435, 1992; and Hamamoto, T. et al., *Bioorg. and Medic. Chem.*, 1, pp.141-145, 1993). Furthermore, cDNAs encoding Gal $\beta$ 1,3GalNAc $\alpha$ 2,3-sialyltransferase (Gal $\beta$ 3GalNAc- $\alpha$ 3ST) (Gillespie, W. et al., *J. Biol. Chem.*, 267, pp.21004-21010, 1992; Japanese Patent Unexamined Publication No. 5-504678/1993; and Lee, Y. et al., *Eur. J. Biochem.*, 216, 377-385, 1993); Gal $\beta$ 1,3(4) GlcNAc $\alpha$ 2,3-sialyltransferase (Gal $\beta$ 3(4)GlcNAc- $\alpha$ 3ST) (Wen, D. X et al., *J. Biol. Chem.*, 267, 21011-21019, 1992; and Kitagawa, H. et al., *Biochem. Biophys. Res. Commun.* 194, 375); and Gal $\beta$ 1,3GalNAc/Gal $\beta$ 1,4GlcNAc $\alpha$ 2,3-sialyltransferase (Sasaki, K. et al., *J. Biol. Chem.*, 268, 22782-22787, 1993) have also been cloned.

With respect to GalNAc $\alpha$ 2,6-sialyltransferase, the isolation of this enzyme has been reported (Hakomori, S., *Ann. Rev. Biochem.*, 50, 733-764, 1981). However, the enzyme has not been purified so as to be characterized as a single identifiable substance, and accordingly, the enzyme has not been practically used because of insufficient reaction specificity, stability, and quantitative availability. Furthermore, a cDNA sequence encoding GalNAc $\alpha$ 2,6-sialyltransferase (EC 2.4.99.3; GalNAc- $\alpha$ 6ST) has not yet been cloned.

Each of the aforementioned sialyltransferases whose structures having been revealed has a hydrophobic segment located at the NH<sub>2</sub>-terminal region, and is a type II transmembrane protein immobilized to cell membrane by the hydrophobic segment. From this reason, a problem arises that expressed enzymes are immobilized to cell membranes and are not capable of being extracellularly released, where expressions are carried out using vectors containing sialyltransferase genes that are transfected into mammalian cells. Furthermore, another problem may arise, when the expression is performed using mammalian cells, that enzyme expressions may be reduced as endoplasmic enzyme concentrations exceed certain levels.

In order to solve the above problems, an extracellularly releasable fused protein may be prepared which comprises an active domain of a sialyltransferase and a signal peptide region. This method is characterized in that a sialyltransferase can be readily recovered from a cell cultivation mixture, because the method involves the step of extracellular release of the fused protein which retains sialyl transfer activity and function as a sialyltransferase. However, where the expression of a sialyltransferase is performed using a mammalian cell, a transfected cell may be unstable or troublesome cultivation procedures are required. In addition, in order to obtain a large quantity of expressed sialyltransferase, a mass cell culture is essential for a long period of time, which may cause disadvantageous from viewpoints of cost and manufactural installations.

Processes are well known to those skilled in the art to obtain cloned cDNA sequence encoding an enzyme expressed in mammalian cells and prepare a recombinant vector containing a gene encoding the enzyme, per se, or in a soluble form, and to transform microorganisms with the vector. A desired enzyme can be produced, in a large quantity, by culturing the transformant obtained by the aforementioned method to allow the microorganism expresses the enzyme, per se, or in a soluble form that has the desired activity.

This process comprises, for example, a step of culturing a transformed microorganism and extracting an expressed enzyme by lysis of the microorganisms using lysozyme or the like. However, a large amount of insoluble or soluble proteins is expressed in the microorganisms in a short period of time, and such proteins may aggregate inside the microorganisms to form proteinic aggregates or precipitates. Accordingly, it is necessary to extract the protein from such aggregates or precipitates.

To extract the desired protein from the aforementioned aggregates or precipitates, generally employed methods are those using urea, guanidine hydrochloride and the like. In this approach, the expressed protein is generally subjected to denaturation using, for example, urea for solubilization (by an exposure of the hydrophobic region), and then to renaturation treatment. The renaturation may be achieved by removing the urea through dialysis. However, for the removal of urea, a problem is that optimal conditions including pH, salt concentration, and temperature must be chosen that are strictly specific to each of the enzymes, and this optimization of conditions is extremely time-consuming. If inappropriate conditions are applied, recovered enzyme may retain almost no activity, and therefore, the selection of the conditions for the renaturation is particularly important.

Accordingly, one object of the present invention is to provide purified GalNAc $\alpha$ 2,6-sialyltransferase. Another object of the present invention is to provide a DNA sequence encoding GalNAc $\alpha$ 2,6-sialyltransferase and an amino acid sequence of the enzyme by cloning a cDNA sequence that encodes GalNAc $\alpha$ 2,6-sialyltransferase. Further objects of the present invention are to provide an extracellularly releasable protein comprising an active domain of the GalNAc $\alpha$ 2,6-sialyltransferase and to provide a process for a mass expression of said protein in microorganisms. It is also an object of the invention to provide a process for extraction of an expressed sialyltransferase from aggregate thereof in microorganisms and a process of efficient renaturation of the extract.

#### SUMMARY OF THE INVENTION

The present inventors conducted various studies to achieve the foregoing objects, and as a result, they succeeded in cloning the cDNA encoding GalNAc $\alpha$ 2,6-sialyltransferase from chick embryo. The present invention was achieved on the basis of these findings. The present invention thus provides GalNAc $\alpha$ 2,6-sialyltransferase P-B1 characterized by the amino acid sequence disclosed as SEQ ID NO.1 in the sequence listings. The present invention also provides GalNAc $\alpha$ 2,6-sialyltransferase genes encoding the aforementioned amino acid sequence of GalNAc $\alpha$ 2,6-sialyltransferase P-B1, and as an embodiment thereof, a GalNAc $\alpha$ 2,6-sialyltransferase gene characterized by the nucleotide sequence from nucleotide No.1 to 1698 disclosed as SEQ ID NO.1 in the sequence listings. Also provided are recombinant vectors comprising the above GalNAc $\alpha$ 2,6-sialyltransferase gene and plasmid  $\lambda$ CEB-3034 as an embodiment thereof, transformants which are transformed with the above recombinant vector, and the active domain of GalNAc $\alpha$ 2,6-sialyltransferase characterized by the amino acids of No. 233 through 566 of the amino acid sequence disclosed as SEQ ID NO.1 in the sequence listings.

The GalNAc $\alpha$ 2,6-sialyltransferase P-B1 has activity of transferring sialic acid to the 6-position of N-acetylgalactosamine directly bound to a protein regardless of the presence or absence of a substituent on hydroxyl group at the 3-position. The structure of NeuAc $\alpha$ 2,6GalNAc-protein is thus readily formed by the enzyme, which terminates further extension of the resulting sugar chain. Therefore, where a longer sugar chain is desired, a sugar chain synthetic scheme should be designed so that this enzyme can be employed after complete extension of a sugar chain. For this reason, a sialyltransferase is highly useful which fails to transfer sialic acid to an N-acetylgalactosamine that has unsubstituted 3-hydroxyl group and bonded to a protein via an  $\alpha$ -glycoside linkage, but can transfer sialic acid to the 6-position of an N-acetylgalactosamine bound to a protein via an  $\alpha$ -glycoside linkage, only when the hydroxyl group at 3-position is substituted with a galactose or a sugar chain having a galactose at its reduced terminus.

Therefore, the inventors of the present invention cloned a cDNA from chicken testes that encodes GalNAc $\alpha$ 2,6-sialyltransferase having the aforementioned features, and as a result, they achieved the present invention relating to the GalNAc $\alpha$ 2,6-sialyltransferase P-B3 characterized by the amino acid sequence disclosed as SEQ ID NO.3 in the sequence listings. The present invention thus provides GalNAc $\alpha$ 2,6-sialyltransferase genes encoding the above amino acid sequence of the GalNAc $\alpha$ 2,6-sialyltransferase P-B3, and as an embodiment thereof, the GalNAc $\alpha$ 2,6-sialyltransferase gene having the nucleotide sequence of from nucleotide No.1 to 1212 as disclosed as the SEQ ID NO.3 in the sequence listings. The present invention also provides a recombinant vector comprising the above GalNAc $\alpha$ 2,6-sialyltransferase gene and plasmid  $\lambda$ CEB3-T20 as an embodiment thereof, and a transformant being transformed with the above recombinant vector.

The inventor of the present invention further conducted studies to provide an extracellularly releasable protein comprising a portion, i.e. active domain, that is derived from the structure of the aforementioned GalNAc $\alpha$ 2,6-sialyltrans-

ferase and is responsible for its activity. As a result, they succeeded in identifying a partial polypeptide of the above-described GalNAc $\alpha$ 2,6-sialyltransferase as being the active domain, and achieved the present invention directed to an extracellularly releasable protein which comprises the polypeptide region together with a signal peptide and catalyzes GalNAc $\alpha$ 2,6-sialic acid transfer. As an embodiment thereof, protein SB-690 characterized by the amino acid sequence disclosed as SEQ ID NO.2 in the sequence listings. The present invention also provides genes encoding the above protein, and as an embodiment thereof, a gene having the nucleotide sequence characterized by from nucleotide No.1 to 1065 disclosed as SEQ ID NO.2 of the sequence listings, and a recombinant vector containing the aforementioned gene and plasmid pcDSB-690 as an embodiment thereof. Further provided are a transformant being transformed with the above recombinant vector and a process for preparing the aforementioned protein which comprises the steps of culturing the above transformant and recovering the above protein from the culture.

In addition, the inventors found that a Gal $\beta$ 1,4GalNAc $\alpha$ 2,6-sialyltransferase with a highly restored activity can be prepared by expressing mouse Gal $\beta$ 1,4GalNAc $\alpha$ 2,6-sialyltransferase in an insoluble form in *Escherichia coli*, followed by extracting the enzyme with urea and subjecting the enzyme to renaturation under optimal conditions, and thus achieved the present invention. In accordance with the present invention, there is provided a process for producing a sialyltransferase which comprises the steps of: (a) expressing a sialyltransferase in a microorganism; (b) extracting the sialyltransferase with about 5 to 9 M urea from proteinic aggregates or precipitates accumulated inside the microorganism and containing the enzyme; (c) diluting the extract obtained by the above step (b) with a renaturation composition to obtain a primary dilution containing about 1 to 4 M urea; (d) diluting the primary dilution obtained by the above step (c) with a renaturation composition to obtain a secondary dilution containing about 0.5 to 2 M urea; and (e) removing urea from the secondary dilution obtained by the above step (d) by dialysis to afford a renatured sialyltransferase.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows a restriction map of the cDNA clone encoding GalNAc $\alpha$ 2,6-sialyltransferase P-B1. In the figure, E represents EcoRI; RV: EcoRV; P: PstI; and B: BglII.

Fig. 2 shows the result of hydrophobicity analysis of the GalNAc $\alpha$ 2,6-sialyltransferase P-B1 according to the present invention. In the figure, N-terminus of the protein is depicted at the left side and positive values indicate hydrophobic regions.

Fig. 3 shows the location of the active domain of the GalNAc $\alpha$ 2,6-sialyltransferase P-B1 according to the present invention and the result of comparison with the structure of protein SB-690 which has GalNAc $\alpha$ 2,6-sialyltransferase activity and can be extracellularly released. In the figure, protein SB-BGL is a protein not having GalNAc $\alpha$ 2,6-sialyltransferase activity.

Fig. 4 shows the result of comparison between the primary sequences of GalNAc $\alpha$ 2,6-sialyltransferase P-B3 and GalNAc $\alpha$ 2,6-sialyltransferase P-B1 according to the present invention. In the figure, amino acids are represented by the one-letter abbreviations.

#### BEST MODE FOR CARRYING OUT THE INVENTION

As the most preferred embodiments of the present GalNAc $\alpha$ 2,6-sialyltransferases, GalNAc $\alpha$ 2,6-sialyltransferases P-B1 and P-B3 are provided. The explanations set out below will detail GalNAc $\alpha$ 2,6-sialyltransferases P-B1 and P-B3 as examples of the enzyme of the present invention. However, the GalNAc $\alpha$ 2,6-sialyltransferases of the present invention are not limited to the GalNAc $\alpha$ 2,6-sialyltransferase P-B1 or P-B3. GalNAc $\alpha$ 2,6-sialyltransferases comprising the active domain of the GalNAc $\alpha$ 2,6-sialyltransferase P-B1 and/or that of P-B3, both were first revealed by the present invention, or alternatively, those comprising one or more active domains of the GalNAc $\alpha$ 2,6-sialyltransferase in which the aforementioned acid sequence is partially changed or modified also fall within the scope of the present invention. A preferred example of such active domains as mentioned above is the active domain of the GalNAc $\alpha$ 2,6-sialyltransferase characterized by from amino acid No.233 to 566 of the amino acid sequence disclosed as SEQ ID NO.1 of the sequence listings.

The methods for isolation of the respective cDNAs encoding GalNAc $\alpha$ 2,6-sialyltransferase P-B1 and GalNAc $\alpha$ 2,6-sialyltransferase P-B3 will be detailed in Examples set out below. However, the methods for isolation of the cDNAs encoding GalNAc $\alpha$ 2,6-sialyltransferase P-B1 and GalNAc $\alpha$ 2,6-sialyltransferase P-B3 are not limited to those methods. One of ordinarily skilled artisan can readily isolate the desired cDNAs by referring to the methods described in the following examples, or alternatively, by appropriately modifying or altering those methods. In addition, the nucleotide sequences disclosed as SEQ ID Nos.1 through 3 in the sequence listings may be synthetically prepared and used to carry out the present invention.

The DNA sequence encoding GalNAc $\alpha$ 2,6-sialyltransferase P-B1 as defined by SEQ ID No.1 in the sequence listings and the DNA sequence encoding GalNAc $\alpha$ 2,6-sialyltransferase P-B3 as defined by SEQ ID No.3 are the preferred embodiments of the present invention. However, the DNA sequences encoding GalNAc $\alpha$ 2,6-sialyltransferase P-B1 or GalNAc $\alpha$ 2,6-sialyltransferase P-B3 of the present invention are not limited to those specified embodiments, and any

one of DNA sequences encoding the respective amino acid sequences of GalNAc $\alpha$ 2,6-sialyltransferase P-B1 and GalNAc $\alpha$ 2,6-sialyltransferase P-B3 revealed by the present invention fall within the scope of the present invention. For example, the DNA sequence encoding the active domain of GalNAc $\alpha$ 2,6-sialyltransferase characterized by the amino acids of from No. 233 to 566 of the amino acid sequence as defined by SEQ ID No.1 in the sequence listings is a preferred embodiment of the present invention. In addition, the DNA characterized by the nucleotides sequence of from nucleotide No. 699 to 1698 of the SEQ ID No.1 shown in the sequence listings is a particularly preferred embodiment of the present invention.

The GalNAc $\alpha$ 2,6-sialyltransferases of the present invention, including P-B1 and P-B3 for example, may occasionally be retained inside the cells after expression and not released extracellularly. Furthermore, when endoplasmic concentrations of the enzymes exceed certain levels, expressed amounts of the enzymes may possibly be reduced. In order to efficiently utilize the aforementioned GalNAc $\alpha$ 2,6-sialic acid transfer activities of GalNAc $\alpha$ 2,6-sialyltransferase P-B1 and P-B3, proteins in soluble forms may be prepared in which the activities of these enzymes are retained and can be released extracellularly from cells upon their expressions. Examples of such proteins include, for example, extracellularly releasable proteins which comprise a polypeptide, as being an active domain of the above-described GalNAc $\alpha$ 2,6-sialyltransferase P-B1 or P-B3 and is responsible for the GalNAc $\alpha$ 2,6-sialyltransferase activity, and catalyze the GalNAc $\alpha$ 2,6-sialic acid transfer.

The sialyltransferases so far cloned have domain structures similar to those of other glycosyltransferases: a short NH<sub>2</sub>-terminal cytoplasmic tail; a hydrophobic signal-anchor domain; a proteolytically sensitive stem region; and a large COOH-terminal active domain (Paulson, J.C. and Colley, K.J., J. Biol. Chem., 264, 17615-17618, 1989). To determine the location of the transmembrane domain of the GalNAc $\alpha$ 2,6-sialyltransferase P-B1 of the present invention, hydrophathy plot may be used which can be prepared according to the method of Kyte and Doolittle (Kyte, J. and Doolittle, R.F., J. Mol. Biol., 157, 105-132, 1982). To evaluate a putative active domain, recombinant plasmids introduced with various fragments may be produced and utilized. Exemplary methods will be detailed in the Examples set out below. However, the methods for determination of the location of the transmembrane domain or evaluation of a putative active domain are not limited to the disclosed methods.

For the preparation of the extracellularly releasable protein comprising a polypeptide portion, as being an active domain of the above-described GalNAc $\alpha$ 2,6-sialyltransferase P-B1 or P-B3, together with a signal peptide, an immunoglobulin signal peptide sequence, for example, may be used as the signal peptide, and a sequence corresponding to the active domain of GalNAc $\alpha$ 2,6-sialyltransferase P-B1 or P-B3 may be fused in-frame to the signal peptide. For example, the method of Jobling et al. (Jobling, S.A. and Gehrke, L., Nature (Lond.), 325, 622-625, 1987) may be applied as such methods, whose specified procedure will be detailed in the Examples of the present specification with respect to GalNAc $\alpha$ 2,6-sialyltransferase P-B1. However, types of the signal peptide and methods for ligation of the signal peptide and the active domain are not limited to the aforementioned methods, and a person skilled in the art can suitably choose the polypeptide portion as being an active domain of GalNAc $\alpha$ 2,6-sialyltransferase, preferably GalNAc $\alpha$ 2,6-sialyltransferase P-B1 or P-B3, and produce the extracellularly releasable protein by ligating the polypeptide portion to any available signal peptide according to an appropriate method. The most preferred example of these proteins is protein SB-690 of the present invention.

According to another embodiment of the present invention, there is provided a process for producing a sialyltransferase which comprises the steps of: (a) expressing a sialyltransferase in a microorganism; (b) extracting the sialyltransferase with about 5 to 9 M urea from proteinic aggregate or precipitate containing the enzyme and being accumulated inside the microorganism; (c) diluting the extract obtained by the above step (b) with a renaturation composition to obtain a primary dilution containing about 1 to 4 M urea; (d) diluting the primary dilution obtained by the above step (c) with a renaturation composition to obtain a secondary dilution containing about 0.5 to 2 M urea; and (e) removing urea from the secondary dilution obtained by the above step (d) by dialysis to afford a renatured sialyltransferase. As described above, sialyltransferases share the common domainal structure, and therefore, the preparation process of the present invention may be applicable to any type of sialyltransferase. For example, GalNAc $\alpha$ 2,6-sialyltransferase or Gal $\beta$ 1,4GalNAc $\alpha$ 2,6-sialyltransferase of the present invention can be suitably prepared by the process of the present invention.

According to an embodiment of the process of the present invention, 8 M urea is used in the step (b); a primary dilution containing about 2 to 3 M urea is obtained in the step (c); a secondary dilution containing about 1 to 2 M urea is obtained in the step (d); and the secondary dilution is dialyzed in the presence of divalent cations in the step (e). According to another embodiment of the present method, 8 M urea is used in the step (b); a primary dilution containing about 2 to 3 M urea is obtained by being left stand for 12 hours or more at 4 °C after primary dilution in the step (c); a secondary dilution containing about 1 to 2 M urea is obtained by being left stand for 48 hours or more after secondary dilution in the step (d); and the secondary dilution is dialyzed in the presence of divalent cations in the step (e). In addition, it is also a preferred method in which the renaturation composition used in the step (c) contains 1 to 2 M urea, 20 mM MOPS-NaOH, 0.5M NaCl, 20 mM lactose, 0.5 mM EDTA (pH 7.0) and the renaturation composition used in the step (d) contains 20 mM MOPS-NaOH, 0.5M NaCl, 20 mM lactose, 0.5 mM EDTA (pH 7.0).

The first step of the process for the preparation of sialyltransferase according to the present invention is the expression of a sialyltransferase in microorganisms. To this end, previously cloned genes of sialyltransferases can be used. As cDNAs encoding sialyltransferases, the cDNA encoding Gal $\beta$ 1,4GlcNAc $\alpha$ 2,6-sialyltransferase (Gal $\beta$ 4GlcNAc- $\alpha$ 6ST, see, Weinstein et al., Grundmann et al., Bast et al. and Hamamoto et al., supra), the cDNA encoding Gal $\beta$ 1,3(4)GlcNAc $\alpha$ 2,3-sialyltransferase (Gal $\beta$ 3(4)GlcNAc- $\alpha$ 3ST, see, Wen et al. and Kitagawa et al., supra), the cDNA encoding Gal $\beta$ 1,3GalNAc/Gal $\beta$ 1,4GlcNAc $\alpha$ 2,3-sialyltransferase (see, Sasaki et al., supra), the cDNA encoding Gal $\beta$ 1,3GalNAc $\alpha$ 2,3-sialyltransferase (Gal $\beta$ 3GalNAc- $\alpha$ 3ST, see, Gillespie et al. and Japanese Patent Unexamined Publication No. 5-504678/1993; and Lee et al., supra), for example, may be used, as well as cDNAs encoding the GalNAc $\alpha$ 2,6-sialyltransferases of the present invention. Sialyltransferase genes contained in these nucleotide sequences, per se, may be used for the expression of the naturally-derived enzymes.

According to the present invention, in addition to the naturally-derived sialyltransferases mentioned above, non-natural sialyltransferases in which the polypeptide sequences of the naturally-derived sialyltransferases are partly deleted or modified may be expressed in microorganisms. For example, since sialyltransferases have a hydrophobic segment (transmembrane domain) in the NH<sub>2</sub>-terminal region, and sialyltransferases in soluble forms wherein the hydrophobic segment is deleted are preferably expressed in the microorganisms. In addition, deletion of both of the hydrophobic segment and the cytosol segment is also preferred.

In order to produce recombinant vectors for the expression of sialyltransferases, the entire sequences or partial regions of the genes of naturally derived sialyltransferases may be selectively amplified by, for example, PCR method. For example, a sialyltransferase gene (a PCR fragment) may be readily prepared which has an initiation codon and a cloning site and lacks the cytosol domain and transmembrane domain. This type of sialyltransferase genes are suitably used for the introductions into vectors for microbial expressions due to the presence of the initiation codon and the cloning site. In addition, said genes are preferred since they encode non-natural sialyltransferases, in which a part of the polypeptide sequence of the naturally-derived sialyltransferase is deleted, and express non-natural soluble sialyltransferase in microorganisms.

According to the process of the present invention, microorganisms such as *Escherichia coli* may be used for the expression of sialyltransferase. A microbial expression vector suitably used for transformation of such microorganisms may be suitably selected by an ordinarily skilled artisan. For example, where *E. coli* JM109(DE3) or the like is used as the microorganism, microbial expression vectors such as pET3b (Studier, F.W. et al., Method. Enzymol., 185, pp.60-89, 1990) may be used. Methods for introducing the above described sialyltransferase genes into microbial expression vectors and methods for transforming microorganisms with recombinant vectors are both well known to those skilled in the art.

The transformants can be cultured according to methods for culturing transformed microorganisms well known to those skilled in the art. For efficient expression of a desired sialyltransferase in microbial cells, replication of the recombinant protein can be initiated by, for example, the induction of T7-RNA polymerase during the logarithmic growth phase of the transformants. A large amount of naturally-derived or non-natural sialyltransferase is expressed inside the transformants thus obtained, which generally forms proteinic aggregate or precipitate.

The second step of the process of the present invention is the extraction step of a sialyltransferase with 5 to 10 M urea from the proteinic aggregate or precipitate which is accumulated inside the cells and contains the sialyltransferase. In order to expose the proteinic aggregate or precipitate to outside of the microorganisms for its separation, the cultured transformants can be treated with, for example, lysozyme or Triton X-100 and then insoluble fractions may be collected by centrifugation. After then, the precipitates are suspended in a buffer (for example, 10 mM Tris-HCl, pH 7.4) at a protein concentration of about 1 to 10 mg/ml and are subjected to extraction with urea.

For example, solid urea is added to the suspension so as to be 5 to 10 M, preferably 8 M of final concentration, and the precipitates are subjected to extraction for 15 minutes to 2 hours, preferably 30 minutes at 4 to 25 °C, preferably at 10°C. While not bound by any specific theory, the hydrophobic portion of a sialyltransferase contained in the extract is exposed by the action of urea, and as a result, a solubilized sialyltransferase is extracted from the proteinic aggregates or precipitates.

Then, an extract solution containing a denatured sialyltransferase can be obtained by removing the precipitates by, for example, centrifugation of the extract at 12,000 x g for 15 minutes. This extract normally contains about 0.5 mg/ml of proteins. For example, when 5.7 M urea is used for the extraction, about 80% of proteins can be recovered. Furthermore, upon the extraction, NaCl and Tris-HCl (pH 7.4) are preferably added so that their final concentrations of 0.3 M and 20 mM, respectively, are achieved. Exemplary procedure of the extraction will be explained in detail in the Examples set out below.

The sialyltransferase contained in the extract exposes hydrophobic portions and its higher-order structure is damaged. According to the process of the present invention, renaturation of the sialyltransferase contained in the extract is performed as the third step. The term renaturation herein used means restoration of the higher-order structure of the protein that is lost during the extraction step and the entire or partial recovery of the enzymatic activity. This step is characterized in that the extract is diluted stepwise with a renaturation composition so that the urea concentration can be gradually lowered to efficiently achieve the renaturation of the sialyltransferase.

The renaturation process comprises the steps of, for example, diluting the extract with a renaturation composition to obtain a primary dilution containing about 1 to 4 M urea; diluting the primary dilution with a renaturation composition to obtain a secondary dilution containing about 0.5 to 2 M urea; and removing the urea from the secondary dilution by dialysis to afford a renatured sialyltransferase.

A preferred embodiment of the process comprises the steps of, for example, diluting the extract with a renaturation composition to obtain a primary dilution containing about 2 to 3 M urea; diluting the primary dilution with a renaturation composition to obtain a secondary dilution containing about 1 to 2 M urea; and removing the urea from the secondary dilution by dialysis in the presence of one or more divalent cations to afford a renatured sialyltransferase. A further preferred embodiment is a process comprises the steps of, for example, diluting the extract with a renaturation composition and the result is allowed to stand for 12 hours or more at 4°C to obtain a primary dilution containing about 2 to 3 M urea; diluting the primary dilution with a renaturation composition and the result is allowed to stand for 48 hours or more to obtain a secondary dilution containing about 1 to 2 M urea; and removing the urea from the secondary dilution by dialysis in the presence of one or more divalent cations to afford a renatured sialyltransferase.

As the renaturation composition, for example, 2 M urea, 20 mM MOPS-NaOH (MOPS: 3-morpholinopropanesulfonic acid) (pH 7.0), 0.5M NaCl, 10 mM lactose, 0.5 mM EDTA; and 2 M urea, 20 mM Tris-HCl, 0.3M NaCl, 20 mM lactose, 0.5 mM EDTA (pH 7.4) may be used. In addition, a modified composition may be used in which the components of the latter composition may be changed to, for instance, 20 mM Tris-HCl (pH 8.0); 20 mM MOPS-NaOH (pH 7.0); 20 mM MES-NaOH (pH 6.0) (MES: 3-morpholinoethanesulfonic acid); 0.5 M NaCl; 0.1 M NaCl; or 1M urea. Furthermore, compositions not containing urea or lactose may also be used. Among these, 2 M urea, 20 mM MOPS-NaOH, 0.5 M NaCl, 20 mM lactose, 0.5 mM EDTA (pH 7.0) is preferably used. When the concentration of NaCl is below 0.1 M, or pH exceeds 9, renaturation efficiency is undesirably reduced. Generally, a salt concentration of 0.3 to 0.5 M and pH of 6 to 8 are preferred after the addition of the renaturation composition.

The first dilution comprises the step of preparing a primary dilution using the aforementioned renaturation composition so that a final protein concentration of the extract is 0.01 to 0.05 mg/ml, preferably about 0.02 mg/ml. For example, the extract may be diluted 10 to 40-fold, preferably about 20-fold, and a urea concentration may be 1 to 4 M, preferably not higher than about 3 M and not lower than about 2 M. Dilution treatment is generally and preferably performed at 4°C. This primary dilution mixture is left stand for 12 hours or more at 4°C, most preferably for about 12 hours, to initiate gradual renaturation.

The secondary dilution is carried out by diluting the primary dilution with an equal volume of renaturation composition, preferably not containing urea, to achieve approximately the half urea concentration. Through this dilution, urea concentration of the secondary dilution should be lowered to about 0.5 to 2 M, preferably not higher than about 2 M and not lower than 1 M (e.g., 1 to 2 M), and most preferably at about 1.2 M. The secondary dilution is allowed to stand for 40 hours to 2 weeks, preferably 48 to 72 hours, most preferably about 48 hours at 4°C, to proceed gradual renaturation.

After then, to achieve perfect renaturation, the above-obtained secondary dilution is dialyzed against, for example, a renaturation composition free from urea to completely remove remaining urea. The dialysis may be carried out at 4°C for about 48 hours. Dialysis solution may be, for example, any one of buffer solutions in which the sialyltransferase can be stored stably, as well as the renaturation composition.

In addition, by carrying out the primary and secondary dilution and the final dialysis in the presence of one or more divalent cations, renaturation efficiency can be further improved. Examples of the divalent cations include, for example, magnesium ions and manganese ions. These ions may be used at a concentration of 1 to 10 mM, preferably about 5 mM. It is particularly preferred that the dialysis is performed in the presence of one or more divalent cations. When a reducing agent such as dithiothreitol and mercaptoethanol is added before complete removal of urea in the final dialysis step, the enzymatic activity may occasionally be lost. However, after the urea is completely removed, the enzyme restores resistance to the reducing agent to exhibit the sialyltransferase activity.

The present invention will be further explained more specifically by referring to the following examples. However, the scope of the present invention is not limited to these examples.

## Examples

### (A) Preparation of GalNAc $\alpha$ 2,6-sialyltransferase P-B1

In order to obtain a cDNA clone of GalNAc $\alpha$ 2,6-sialyltransferase P-B1, PCR with two degenerate oligonucleotides (ST-107 and ST-205) was performed using chick embryo cDNA as a template. A fragment of the desired size of approximately 150 bp was obtained. Among the PCR recombinants, one clone, designated as CEB1, was found to have a unique amino acid sequence distinct from the known sialylmotifs of Gal $\beta$ 4GlcNAc- $\alpha$ 6STRL (residues 180-225), Gal $\beta$ 3(4)GlcNAc- $\alpha$ 3STRL (residues 158-203), and Gal $\beta$ 3GalNAc- $\alpha$ 3STPS (residues 144-189). The homologies of the sialylmotif of CEB1 with those of Gal $\beta$ 4GlcNAc- $\alpha$ 6STRL, Gal $\beta$ 3(4)GlcNAc- $\alpha$ 3STRL and Gal $\beta$ 3GalNAc- $\alpha$ 3STPS were 56%, 58% and 60%, respectively.

Screening of a 6-day-old chick embryo cDNA library with the cDNA insert from the CEB1 was carried out, and as a result, several cDNA clones were identified. Among them, clone  $\lambda$ CEB-3043 contained a 2.7 kb insert (Fig. 1). To obtain other overlapping clones, a random-primed cDNA library was again screened by hybridization with the 0.8 kb EcoRI-BglII fragment of the 5'-end of the  $\lambda$ CEB-3043. Fifteen clones were isolated from the cDNA library. Among them,

one clone,  $\lambda$ CEBHAD contained a 220 bp insert overlapping with the 5'-end of clone  $\lambda$ CEB-3043 for 160 bp. The combined DNA from these two cDNAs contained a 1.7 kb of open reading frame that ends at a TGA terminal codon at nucleotide 1699. A poly adenylation signal (AATAAA) at 23 nucleotides upstream from the poly(A) sequence exists at the 3'-end. Translation of this open reading frame affords GalNAc $\alpha$ 2,6-sialyltransferase P-B1 of the present invention (occasionally referred to as P-B1 in the the examples) of 566 amino acids with a molecular mass of 64,781, which starts with a methionine codon at nucleotide 1 with a conventional initiation sequence (Kozak, M., Nature (Lond.), 308, 241-246, 1984). The cDNA including a gene encoding the GalNAc $\alpha$ 2,6-sialyltransferase of the present invention, the nucleotide sequence of  $\lambda$ CEB-3043 as being the gene encoding the GalNAc $\alpha$ 2,6-sialyltransferase of the present invention, and the amino acid sequence of the GalNAc $\alpha$ 2,6-sialyltransferase P-B1 of the present invention are shown in the SEQ ID No.1 of the sequence listings.

#### Polymerase chain reaction (PCR)

PCR was performed using degenerate primers [5' primer ST107: TGGGCCTTGGII(A/C)AGGTGTGCTGTTG, and 3' primer ST205: AGGCGAATGGTAGTTTTTG(AT)GCCCCACATC] deduced from conserved regions in Gal $\beta$ 4GlcNAc- $\alpha$ 6STRL (Weinstein, J. et al., J. Biol. Chem., 262, 17735-17743, 1987), Gal $\beta$ 4GlcNAc- $\alpha$ 6STHP (Grundmann, U. et al., Nucleic Acids Res., 18, 667, 1990), and Gal $\beta$ 3GalNAc- $\alpha$ 3STPS (Gillespie, W. et al., J. Biol. Chem., 267, 21004-21010, 1992). To obtain cDNA, poly(A)-rich RNA (2  $\mu$ g) from 3 day-old chick embryos was incubated with an oligo-dT primer (Pharmacia), 1 mM each of dATP, dCTP, dGTP and dTTP, and 2 U/ $\mu$ l of RNase inhibitor (Promega) in 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl<sub>2</sub> and 0.001% gelatin in 50  $\mu$ l for 10 min at 0 °C, and then for further incubation was carried out for 60 min at 42°C after the addition of 100  $\mu$ U Moloney murine leukemia virus reverse transcriptase (BRL).

After heating the reaction mixture at 94°C for 3 min, cDNA prepared from 0.2  $\mu$ g of poly(A)-rich RNA was used for the PCR experiment in a mixture comprising 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.25 mM MgCl<sub>2</sub> 0.001% gelatin, 200  $\mu$ M of each dATP, dCTP, dGTP and dTTP, 2U of Taq DNA polymerase (Promega), and 40 pmoles of each PCR primer in 50  $\mu$ l. PCR amplification, 35 cycles, was carried out, each cycle consisting of denaturation at 96°C for 45 sec, annealing at 50°C for 60 sec, and extension at 72°C for 60 sec. The PCR products were developed on a 3% agarose gel. The DNA fragment corresponding to 150 bp was eluted from the gel (Qiaex kit; Qiagen), blunt-ended and kinated, and then subcloned into the SmaI site of pUC119, and finally sequenced.

#### Construction of a cDNA library

Total RNA was prepared from chick embryos (6-day-old) by the guanidinium thiocyanate method, followed by centrifugation in a 5.7 M CsCl solution (Sambrook, J., Molecular Cloning: a Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. 1989). Poly(A)-rich RNA was purified with oligotex-dT30 (Takara), and then employed for the construction of a cDNA library using  $\lambda$ ZAPII (Stratagene) and cDNA synthesis (Pharmacia) kits with an oligo-dT primer and random primers.

#### Screening of the cDNA library

The amplified cDNA library (1  $\times$  10<sup>6</sup> plaques) was screened with the chick embryo PCR fragments. The plaque-transferred filters were hybridized with <sup>32</sup>P-radiolabeled DNA probes for 12 h at 65°C in 5  $\times$  SSC, 0.02% SDS, 5  $\times$  Denhardt's solution and 10  $\mu$ g/ml denatured salmon sperm DNA, and then washed twice at 65°C for 20 min in 2  $\times$  SSC, 0.1% SDS. To obtain plasmids from the isolated phage clones, phagemid rescue was performed according to the manual of the manufacturer of the  $\lambda$ ZAPII cloning kit (Stratagene). cDNA inserts were excised directly as Bluescript plasmids. Plasmids were produced by the standard molecular cloning method according to Sambrook et al. (Sambrook, J. et al., Molecular Cloning: a Laboratory Manual).

#### DNA sequence analysis

The DNA sequences of the inserts were determined by the dideoxy-chain termination method (Sanger, F. et al., Proc. Natl. Acad. Sci. USA, 74, 5463-5467, 1977) using single-strand DNA as a template for T7-DNA polymerase. The sequencing reaction and electrophoresis were carried out using the AutoRead DNA sequencing kit and a DNA sequencer (Pharmacia). Single strand DNA was prepared from Escherichia coli XL-Blue (Stratagene) after superinfection with helper phage R408 (Stratagene). The sequence data were analyzed with a computer using PC/Gene (Teijin System Technology).



## Northern and Southern blot analyses

To confirm the existence of the gene, Southern blot analysis of chick genomic DNA was performed. Hybridization with the EcoRI cDNA insert of  $\lambda$ CEB-201 gave a single band for the DNA digested with EcoRI and BamHI, and two bands for the DNA digested with HindIII and SacI. This simple hybridization pattern indicates that the cloned cDNA is a single copy gene.

The transcription pattern during embryonic development was examined by Northern blot hybridization. Analysis of RNA from 6, 8 and 10 day-old chick embryos revealed two RNA species of 3.0 and 2.2 kb. The 3.0 kb transcript was abundant and constantly expressed during all embryonal stages. A low level of the 2.2 kb transcript was detected in 6 day-old embryos and its expression was decreased in 8 and 10 day-old embryos. The gene expression was analyzed using 10  $\mu$ g poly(A)-rich RNA obtained from various chicken tissues: brain, heart, liver, lung, kidney, and testis. Very low levels of the 3.0 and the 4.0 kb transcripts was detected in testes, while almost no signals were detected in other tissues. The following description details each of the experiments.

For Northern blots, 5  $\mu$ g of denatured poly(A)-rich RNAs from chick embryo was size-fractionated on formaldehyde-agarose gels and then blotted onto Hybond N+ nylon membranes (Amersham). For Southern blots, 7.5  $\mu$ g of genomic DNA prepared from chick embryos was digested with restriction enzymes EcoRI, BamHI, HindIII and SacI, and then size-fractionated on 0.6% agarose gels. After electrophoresis, the gels were denatured (30 min) in 0.5 N NaOH and 1.5 M NaCl and neutralized (30 min) in 0.5 M Tris-HCl (pH 7.5) and 1.5 M NaCl, and then the DNA was transferred onto Hybond N+ nylon membranes. Both Northern and Southern filters were prehybridized in 50% formamide, 5  $\times$  SSC, 5  $\times$  Denhardt's, 0.5% SDS, and 10  $\mu$ g/ml denatured salmon sperm DNA at 37 °C for 1 h, and then hybridized with a  $^{32}$ P-labelled DNA probe for 12 h under the same conditions as for prehybridization. The probe applied was a 0.6 kb EcoRI cDNA insert of  $\lambda$ CEB-201, which was labeled with a Multiprime Labeling System (Amersham). The filters were washed twice for 10 min at 65°C in 2  $\times$  SSC and 0.1% SDS, followed by washing twice with 0.2  $\times$  SSC and 0.1% SDS at 65°C for 30 min, and then exposed to Kodak XAR film for about one day at -70°C.

The amino acid sequence of the sialyltransferase P-B1 of the invention, which was revealed as described above, shows the following characteristic features that are not observed in sialyltransferases so far known.

(i) All of the sialyltransferases previously cloned are critical Type II membrane proteins. They have a domain structure similar to that of other glycosyl-transferases: a short NH<sub>2</sub>-terminal cytoplasmic tail; a hydrophobic signal-anchor domain; a proteolytically sensitive stem region; and a large COOH-terminal active domain. On the other hand, the sialyltransferase P-B1 of the invention has a large stem region (or intermediate region).

(ii) The sialyltransferase P-B1 of the invention has a PEST region (residues 233-258). It has been known that the amino acid sequences of proteins with intracellular half-lives of less than 2 hours contain one or more regions that are rich in proline, glutamic acid, serine, and threonine residues (referred to as PEST: Rogers, S. et al., Science, 234, 364-368, 1986). These PEST regions are generally flanked by clusters containing several positively charged amino acids. Other sialyltransferases previously known do not have this region.

(iii) Two stretches of eight amino acids (SSSXVSTC) were found at residues 247-254 and 330-337. A search of the Genebank database for other proteins revealed no sequence similarity to this sequence.

Sialyltransferases so far known exhibit remarkable tissue-specific expression, which seems to be correlated with the existence of cell type-specific carbohydrate structures (Paulson, J.C. and Colley, K.J., J. Biol. Chem., 264, pp.17615-17618, 1989). The results of Northern blotting indicates that the pattern of expression of sialyltransferase P-B1 apparently changes. The transcriptions of three different sizes of mRNAs (4.0, 3.0 and 2.2 kb) from the sialyltransferase P-B1 gene suggests that they are generated through alternative splicing and alternative promoter utilization mechanisms as observed for Gal $\beta$ 1,4GlcNAc $\alpha$ 2,6-sialyltransferase (Gal $\beta$ 4GlcNAc- $\alpha$ 6STRL) and Gal $\beta$ 1,3(4)GlcNAc $\alpha$ 2,3-sialyltransferases (Gal $\beta$ 3(4)GlcNAc- $\alpha$ 3STRL, Weinstein, J. et al., J. Biol. Chem., 262, 17735-17743, 1987; and Wen, D.X. et al., J. Biol. Chem., 267, 21011-21019, 1992). This hypothesis is supported by the results of Southern hybridization, which showed the existence of a single copy gene for sialyltransferase P-B1.

#### (B) Preparation of the soluble form protein SB-690

In order to utilize the GalNAc $\alpha$ 2,6-sialyltransfer activity of the GalNAc $\alpha$ 2,6-sialyltransferase P-B1 of the present invention, protein SB-690 in a soluble form was prepared which retains the activity of the present enzyme and is released from the cells upon expression.

The sialyltransferases so far cloned have a domain structure similar to that of other glycosyl-transferases: a short NH<sub>2</sub>-terminal cytoplasmic tail; a hydrophobic signal-anchor domain; a proteolytically sensitive stem region; and a large COOH-terminal active domain. To determine the location of any transmembrane domain of GalNAc $\alpha$ 2,6-sialyltransferase of the present invention, a hydropathy plot (Fig.2) was prepared from the translated sequence according to the method of Kyte and Doolittle (Kyte, J. and Doolittle, R.F., J. Mol. Biol., 157, 105-132, 1982). As a result, it is suggested

that a critical hydrophobic transmembrane domain of GalNAc $\alpha$ 2,6-sialyltransferase P-B1 of the present invention consists of 21 amino acid residues from the amino acid No.17 to 37.

As described above, the hydrophobic signal anchor domain of GalNAc $\alpha$ 2,6-sialyltransferase is located from amino acid residue No.17 to 37. Residues from 233 to 269 apparently contain certain essential residues for the enzymatic activity, because the media from cells transfected with pcDSB-BGL had no significant activity, while the protein (33 KDa) was synthesized in an in vitro translation/transcription system with pSB-BGL as a template. The active domain was thus deduced to be around 233-566 (Fig.3), which is a comparative size to that of other cloned sialyltransferases. In order to produce the soluble protein containing the active domain described above, the sequence relating to the putative active domain of P-B1 was in-frame fused to the sequence of immunoglobulin signal peptide (Jobling, S.A. and Gehrke, L., Nature (Lond.), 325, 622-625, 1987). Details of the experiments are shown below.

A vector plasmid pUGS was constructed by replacing the PstI-XhoI fragment of the p Bluescript SK(+) plasmid with a 117 bp of a synthetic DNA fragment. This fragment contains 43 bp of the 5'-untranslated leader sequence of Alfalfa Mosaic Virus (Jobling, S.A. and Gehrke, L., Nature (Lond.) 325, 622-625, 1987) with a synthetic PstI site at the 5'-end, followed by the mouse immunoglobulin M heavy chain signal peptide sequence (57 bp) (Boersch-Supan, M.E. et al., J. Exp. Med. 161, 1272-1292, 1985) with a 17 bp of a synthetic EcoRI, BglII and XhoI cloning site at the 3'-end. The nucleotide

5' - CTGCAGGGTTTTTATTTTAAATTTCTTTCAAATA

CTTCCACCATGAAATTCAGCTGGGTCATGTTCTTCCTGATGGCAGTGGTTACAGGGGTCAATTCAGAA

TTCCAGATCTCGAG-3'.

sequence of this fragment is

$\lambda$ CEB-3043 encoding GalNAc $\alpha$ 2,6-sialyltransferase of the present invention was partially digested with EcoRV, and 1.8 kb fragment was subcloned into EcoRV site of pBluescript SK(+) to generate pCEB-1800. This clone lacks 0.8 kb of 3'-untranslated region of  $\lambda$ CEB-3043. An active domain of GalNAc $\alpha$ 2,6-sialyltransferase P-B1 was generated by PCR using the 5'-primer, 5'-AGGGCTGCTGAATTCAGTGAACACAG-3' (nucleotides 679-708), with a synthetic EcoRI site at the middle of the primer and a 3' universal M13 sequencing primer and pCEB-1800 as a template. The PCR product was digested with EcoRI and XhoI, and then ligated into the EcoRI/XhoI site of pUGS to yield the plasmid pSB-690. In this plasmid, a sequence obtained by in-frame fusion of the 3'-end of the immunoglobulin signal sequence to the putative active domain of GalNAc $\alpha$ 2,6-sialyltransferase P-B1 was contained. The fusion fragment was excised from pSB-690 with PstI and XhoI, and then inserted into the PstI/XhoI site of expression vector pcDSR $\alpha$  to yield pcDSB-690.

As a control, protein SB-BGL which lacks the active domain of GalNAc $\alpha$ 2,6-sialyltransferase was produced as described below. pCEB-1800 and pUGS were digested with BglII, and the protruding ends were filled by using the Klenow fragment of DNA polymerase. After heat denaturation of the Klenow fragment of DNA polymerase (at 94 °C for 20 min), these plasmids were digested with XhoI. The 1.0 kb fragment from pCEB-1800 was gel purified and subcloned into the blunt-ended BglII/XhoI site of pUGS to yield pSB-BGL. The PstI/XhoI fragment from pSB-BGL was subcloned into the PstI/XhoI site of pcDSR $\alpha$  to generate pcDSB-BGL.

Expression of the above described protein was performed as follows. COS-7 cells were transiently transfected with 5  $\mu$ g of plasmid DNA using the DEAE-dextran method (McCutchan, J.H. and Pagano, J.S. J. Natl. Cancer Inst. 41, pp.351-357, 1968). The media were harvested after 48 h transfection and then concentrated 10 times on Centricon 30 filters (Amicon) for the enzyme assay. For metabolic labeling, COS cells (60-mm culture dish) were washed with Met-free medium (Dulbecco's modified Eagle's medium and 2% fetal calf serum) (GIBCO) and then incubated for 1 h with the same media. The cells were pulse-labeled with 10 MBq/dish of Express <sup>35</sup>S protein labeling mix (Du Pont-New England Nuclear) in 1.5 ml of Met-free media for 2 h. These cells were then washed with Met-free media and chased for 5 h in media without Express-label. The media containing secreted proteins were harvested, concentrated 10 times, and then subjected to SDS-PAGE, followed by fluorography.

The enzyme activity of the expressed protein was measured as follows. The assays using oligosaccharides and glycoproteins as acceptors were performed in the presence of 50 mM sodium cacodylate buffer (pH 6.0), 50  $\mu$ M CMP-[<sup>14</sup>C]-NeuAc (0.9 Bq/pmol), 1 mg/ml of bovine serum albumin, 2 mg/ml of acceptor substrate and 1  $\mu$ l of concentrated COS cell medium, in a final volume of 10  $\mu$ l, and were incubated at 30 °C for 2 h. At the end of the incubation period, 1  $\mu$ l of the assay mixture was applied to a Silica gel 60HPTLC plate (Merck, Germany). The plate was developed with ethanol:pyridine:n-butanol:water:acetate (100:10:10:30:3), and the radioactivity was visualized and quantified with a BAS2000 radio image analyzer (Fuji Photo Film, Japan). The radioactivity remaining at the origin was taken as sialylated glycoprotein.

Identification of the sialylated products was carried out as follows. Asialo-BSM were resialylated with CMP-[<sup>14</sup>C]-NeuAc in pcDSB-690 COS cell medium and  $\beta$ -elimination oligosaccharides were prepared.  $\beta$ -elimination was car-

ried out according to Carlson's method (Carlson, D.M., J. Biol. Chem., 243, 616-626, 1968). Asialo-BSM (100 µg each) was sialylated with CMP-[<sup>14</sup>C]NeuAc in pcDSB-690 COS cell medium under the same conditions as above, except that the incubation period was 12 h. The reaction was terminated by adding 500 µl of 1% phosphotungstic acid in 0.5M HCl, followed by centrifugation at 10,000 × g for 5 min. The pellets were washed once with the same phosphotungstic acid solution and once with methanol, dissolved in 0.5 ml of 0.05M NaOH and 1M NaBH<sub>4</sub>, and then incubated 30 h at 45°C.

At the end of the incubation period, the solution was neutralized with acetic acid to pH 6 and then lyophilized. The dehydrated products were dissolved in 50 µl of water, and then desalted by gel filtration on a Sephadex G-15 column (0.5 × 5 cm) equilibrated and eluted with water. The radioactive fractions were subjected to thin layer chromatography for identification of the products without further purification. NeuAcα2,6GalNAc-ol and GlcNAcβ1,3[NeuAcα2,6]GalNAc-ol from native BSM in two different developing solvent were co-migrated. The ratio of the transferred sialyl residue was 1:0.9:0.6. The results of the co-migration of Sialylated GalNAc-SerNAc with NeuAcα2,6GalNAc-SerNAc in the two different solvent systems indicate that the protein SB-690 of the present invention forms the NeuAcα2,6 linkage to GalNAc that is directly attached to Ser or Thr residues in glycoproteins.

Media from cells transfected with pcDSB-690 contained sialyltransferase activity and it provide strong evidence that the protein SB-690 of the present invention expressed by pcDSB-690 was secreted out of cells while retaining sialyltransferase activity. On the other hand, media obtained from cells transfected with cDSB-BGL had no sialyltransferase activity.

The acceptor specificity of the protein SB-690 of the present invention was examined with the concentrated COS-7 cell culture medium transfected with pcDSB-690. As shown in Table 1, asialo-mucin, fetuin and asialo-fetuin served as good acceptors. Remarkably, fetuin was shown to be a better acceptor than asialo-fetuin (Baubichon-Cortay, H. et al., Carbohydr. Res., 149, 209-223, 1986; and Brockhausen, I. et al., Biochemistry, 29, 10206-10212, 1990). Other glycoproteins, oligosaccharides and glycolipids did not serve as acceptors, except GalNAc-SerNAc. These data suggest that the acceptor site is GalNAc directly attached to Ser or Thr residues in glycoproteins through an α-glycoside linkage.

Table 1

Acceptor specificity of the protein SB-690 of the invention	
Acceptor	Pmoles/hr/10 µl medium
Fetuin	142
Asialo-fetuin	96
α1 acid glycoprotein	6
Asialo-α1 acid glycoprotein	4
Bovine submaxillary mucin	15
Bovine submaxillary asialo-mucin	186
Ovomucoid	7
Asialo-ovomucoid	0
Galβ1,3GlcNAcβ1,3Galβ1,4Glc	0
Galβ1,4GlcNAc	0
Galβ1,3GalNAc	0
GalNAcβ1,4 Gal	0
Galβ1,4Glc	0
Galactose	0
Ganglioside mixture	0
Ganglioside GD1a	0
GalNAc-SerNAc	4
Benzyl-GalNAc	2

\* A number of 0 indicates less than 1 pmol/hr/10 µl medium.

So far cloned sialyltransferases only exhibit acceptor specificity for the Gal-moiety. While the GalNAc $\alpha$ 2,6-sialyltransferase P-B1 and protein SB-690 of the present invention exhibit acceptor specificity for the GalNAc- but not the Gal-moiety. The following evidence supports that GalNAc $\alpha$ 2,6-sialyltransferase P-B1 and the protein SB-690 of the present invention have the activity of GalNAc $\alpha$ 2,6-sialyltransferase, which transfer CMP-NeuAc with an  $\alpha$ 2,6-linkage onto a GalNAc residue O-linked to Thr/Ser of a glycoprotein:

(i) The expression of pcDSB-690 in COS cells reveals the remarkable acceptor specificity for only the GalNAc moiety bound to Ser/Thr residues, while no detectable enzyme activity was found toward the other substrates tested (Table 1).

(ii) The sialylated products obtained from bovine submaxillary asialo-mucin and GalNAc-SerNAc were shown to have sialic acid bound to the GalNAc moiety through an  $\alpha$ 2,6-linkage.

The two types, i.e., bovine submaxillary gland- and liver (brain)- types, of GalNAc- $\alpha$ 6ST were reported, which have the different acceptor specificity (Bergh, M.E. et al., J. Biol. Chem., 258, 7430-7436, 1983). The former enzyme has the broad specificity toward GalNAc, Gal $\beta$ 1,3GalNAc and NeuAc $\alpha$ 2,3Gal $\beta$ 1,3GalNAc, whereas the latter has only toward NeuAc $\alpha$ 2,3Gal $\beta$ 1,3GalNAc moiety of glycoproteins. The acceptor specificities of the GalNAc $\alpha$ 2,6-sialyltransferase P-B1 and the protein SB-690 of the present invention were found to be similar to that of the former enzyme.

Examination of the acceptor site of asialo-mucin showed that NeuAc $\alpha$ 2,6GalNAc-Ser/Thr was the most abundant product. However, considering the ratio of glycoconjugates in bovine submaxillary asialo-mucin, i.e., GalNAc-Ser/Thr, GlcNAc $\beta$ 1,3GalNAc-Ser/Thr, and Gal $\beta$ 1,3GalNAc-Ser/Thr amounted to 65%, 25%, and 5%, respectively (Tsuji, T. and Osawa, T., Carbohydr. Res., 151, pp.391-402, 1986), GalNAc $\alpha$ 2,6-sialyltransferase P-B1 and the protein SB-690 of the present invention seem to have the following acceptor preference: Gal $\beta$ 1,3GalNAc-Ser/Thr > GlcNAc $\beta$ 1,3GalNAc-Ser/Thr > GalNAc-Ser/Thr. On the other hand, the facts that almost all the radioactivity was released on weak alkali treatment and that fetuin is preferred over asialo-fetuin (Table 1) indicate that NeuAc $\alpha$ 2,3Gal $\beta$ 1,3GalNAc-Ser/Thr is a preferred substrate over Gal $\beta$ 1,3GalNAc-Ser/Thr, as reported for calf liver (Bergh, M.E. et al., J. Biol. Chem., 258, 7430-7436, 1983) and rat brain (Baubichon-Cortay, H. et al., Carbohydr. Res., 149, 209-223, 1986) GalNAc $\alpha$ 2,6-sialyltransferases.

The sialylation of GalNAc-SerNAc was much slower than that of corresponding residues on asialo-mucin (Table 1). Brockhausen et al. (Brockhausen et al., Biochemistry, 29, 10206-10212, 1990) showed that a length of at least five amino acid is required for efficient synthetase activity. A similar effect of the peptide portion directly on GalNAc $\alpha$ 2,6-sialyltransferase P-B1 and the protein SB-690 of the present invention is also suggested from this observation (Table 1).

The reagents and the like used in the above preparation examples (A) and (B) were as follows: Fetuin, asialo-fetuin, bovine submaxillary mucin,  $\alpha$ 1-acid glycoprotein, galactose  $\beta$ 1,4-N-acetylgalactosamine, CMP-NeuAc, lacto-N-tetraose, benzyl-GalNAc, N-acetyllactosamine, and Triton CF-54 were obtained from Sigma (St. Louis, USA). CMP[ $^{14}$ C]NeuAc(11 GBq/mmol) was obtained from Amersham (U.K.). N-Acetylgalactosamine  $\beta$ 1,4-galactose was a gift from Dr. Kajimoto (The Institute of Physical and Chemical Research, RIKEN, Wako-shi, Saitama-ken, Japan). 2-Acetamide and 2-deoxygalactosyl- $\alpha$ N-acetylserine (GalNAc-SerNAc) were synthesized according to Grundler and Schmidt (Grunder G., and Schmidt R.R., Liebigs Ann. Chem., 1984, 1826-1847, 1984). NeuAc $\alpha$ 2,6-GalNAc-SerNAc was prepared from NeuAc $\alpha$ 2,6GalNAc-Ser (MECT) by acetylation with anhydroacetate in pyridine-water. NeuAc $\alpha$ 2,6GalNAc-ol and GlcNAc $\beta$ 1,3[NeuAc $\alpha$ 2,6]GalNAc-ol were prepared from bovine submaxillary mucin according to Tsuji and Osawa (Tsuji, T. and Osawa T., Carbohydr. Res., 151, 391-402, 1986) and identified by 270MHz  $^1$ H and  $^{13}$ C NMR (Savage, A.V. et al., Eur. J. Biochem., 192, pp. 427-432, 1990; and Savage, A.V. et al., Eur. J. Biochem., 193, 837-843, 1990). Synthetic primers were synthesized with the Applied Biosystem 394 DNA synthesizer. Restriction endonucleases SmaI, EcoRI, BamHI, HindIII, SacI, XhoI, BglII and PstI were from Takara (Japan).

#### (C) Preparation of GalNAc $\alpha$ 2,6-sialyltransferase P-B3

In order to obtain cDNA clones of GalNAc $\alpha$ 2,6-sialyltransferases, PCR with two degenerate oligonucleotides (ST-107 and ST-205) was performed with chick embryo cDNA as a template. The fragment of the desired size of approximately 150 bp was purified by agarose gel electrophoresis. As a result of sequencing of the PCR products, it was revealed that they included those encoding Gal $\beta$ 1,4GlcNAc $\alpha$ 2,6-sialyltransferase (Kurosawa, N., et al., Eur. J. Biochem., 219, 375-381, 1994) and GalNAc $\alpha$ 2,6-sialyltransferase P-B1, as well as a PCR product encoding a novel amino acid sequence, pCRB3. The identity of the sialylmotif of pCRB3 with those of above-mentioned sialyltransferases was 65 through 57%.

In order to identify the complete coding sequence of the gene, a young chicken testis cDNA library was screened with the cDNA insert of pCRB3. The screening about  $5 \times 10^5$  independent clones yielded one positive clone,  $\lambda$ CEB3-T20, which has an insert size of 2.05 kb.

The nucleotide sequence of the cDNA clone included an open reading frame of 1212 bp, coding for 404 amino acids with a molecular mass of 45.8 kDa. The open reading frame starts with a methionine codon at nucleotide 1, with

a conventional translation initiation sequence (Kozak, M. *Nature*, 308, 241-246, 1984), and ends with a TGA stop codon at nucleotide 1213. The open reading frame is flanked by a 5'-untranslated sequence of 384 bp and a 3'-untranslated sequence of 451 bp. The DNA sequence 5' of the initiation site contains stop codons in all three reading frames. The nucleotide sequence and deduced amino acid sequences of  $\lambda$ CEB3-T20 are shown in the SEQ ID No.3 of the sequence listings. The GalNAc $\alpha$ 2,6-sialyltransferase having this amino acid sequence was designated as P-B3.

This GalNAc $\alpha$ 2,6-sialyltransferase P-B3 (when the GalNAc $\alpha$ 2,6-sialyltransferase P-B1 is referred to as ST6GalNAcA, this enzyme is occasionally referred to as ST6GalNAcB) has type II transmembrane domain, containing a 17-amino acid N-terminal hydrophobic sequence bordered by charged residues, as has been found for all sialyltransferases cloned to date. Comparison of the primary sequence of GalNAc $\alpha$ 2,6-sialyltransferase P-B3 with other amino acid sequences in DNA and protein data banks revealed similarities in two regions to all of the cloned sialyltransferases.

One region (sialylmotif L) in the center of the GalNAc $\alpha$ 2,6-sialyltransferase P-B3, consisting of a 45 amino acid stretch, shows 64-24% sequence identity, whereas the other, in the COOH-terminal portion (sialylmotif S, residues 333-355), exhibits 78-43% identity. The overall amino acid sequence identity of GalNAc $\alpha$ 2,6-sialyltransferase P-B3 is 10% to chick Gal $\beta$ 1,4GlcNAc $\alpha$ 2,6-sialyltransferase (Kurosawa, N., et al., *Eur. J. Biochem.*, 219, 375-381, 1994), 13% to chick Gal $\beta$ 1,3GalNAc $\alpha$ 2,3-sialyltransferase (Kurosawa N. et al., *Biochem. Biophys. Acta.*, 1244, 216-222, 1995), and 32% to chick ST6GalNAcA (22), respectively. These results suggest that the cloned gene belongs to the sialyltransferase gene family.

Details of the experiments are as follows.

#### 20 Polymerase chain reaction (PCR)

PCR was performed using degenerate primers [5' primer ST107: TGGGCCTTGII(A/C)AGGTGTGCTGTTG, and 3' primer ST205: AGGCGAATGGTAGTTTTTG(A/T)GCCCACATC] deduced from conserved regions in Gal $\beta$ 4GlcNAc- $\alpha$ 6STRL (Weinstein, J. et al., *J. Biol. Chem.*, 262, 17735-17743, 1987), Gal $\beta$ 4GlcNAc- $\alpha$ 6STHP (Grundmann, U. et al., *Nucleic acids Res.*, 18, 667, 1990), and Gal $\beta$ 3GalNAc- $\alpha$ 3STPS (Gillespie, W. et al., *J. Biol. Chem.*, 267, 21004-21010, 1992). To obtain cDNA, poly(A)-rich RNA (2  $\mu$ g) from 3 day-old chick embryos was incubated with an oligo-dT primer (Pharmacia), 1 mM each of dATP, dCTP, dGTP and dTTP, and 2 U/ $\mu$ l of RNase inhibitor (Promega) in 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl<sub>2</sub> and 0.001% gelatin in 50  $\mu$ l for 10 min at 0 °C, and then for additional 60 min at 42°C after the addition of 100  $\mu$ U Moloney murine leukemia virus reverse transcriptase (BRL).

After heating at 94 °C for 3 min, cDNA prepared from 0.2  $\mu$ g of poly(A)-rich RNA was used for the PCR experiment in a mixture comprising 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.25 mM MgCl<sub>2</sub>, 0.001% gelatin, 200  $\mu$ M of each dATP, dCTP, dGTP and dTTP, 2U of Taq DNA polymerase (Promega), and 40 pmoles of each PCR primer in 50  $\mu$ l. PCR amplification, 35 cycles, was carried out, each cycle consisting of denaturation at 96°C for 45 sec, annealing at 50 °C for 60 sec, and extension at 72°C for 60 sec. The PCR products were developed on a 3% agarose gel. The DNA fragment corresponding to 150 bp was eluted from the gel (Qiaex kit; Qiagen), blunt-ended, kinased, and then subcloned into the SmaI site of pUC119, and finally sequenced.

#### Construction of a cDNA library

Total RNA was prepared from chick embryos (6 day-old) by the guanidinium thiocyanate method, followed by centrifugation in a 5.7 M CsCl solution (Sambrook, J., *Molecular Cloning: a Laboratory Manual*, 2nd edition). Poly(A)rich RNA was purified with Oligotex-dT30 (Takara), and then employed for the construction of a cDNA library using  $\lambda$ ZAPII (Stratagene) and cDNA synthesis kits (Pharmacia) with an oligo-dT primer and random primers.

#### 45 Screening of the cDNA library

The amplified cDNA library ( $1 \times 10^6$  plaques) was screened with the chick embryo PCR fragments. The plaque-transferred filters were hybridized with <sup>32</sup>P-radiolabeled DNA probes for 12 h at 65°C in 5  $\times$  SSC, 0.2% SDS, 5  $\times$  Denhardt's solution, and 10  $\mu$ g/ml denatured salmon sperm DNA. The filters were then washed twice at 65°C for 20 min in 2  $\times$  SSC, 0.1% SDS. To obtain plasmids from the isolated phage clones, phagemid rescue was performed according to the instructions of the manufacturer of the  $\lambda$ ZAPII cloning kit (Stratagene). cDNA inserts were excised directly as Bluescript plasmids. Plasmids were produced by the standard molecular cloning method according to Sambrook, et al. (Sambrook, J. et al., *Molecular Cloning: a Laboratory Manual*, 2nd ed.).

#### 55 DNA sequence analysis

The DNA sequences of the inserts were determined by the dideoxy-chain termination method (Sanger, F. et al., *Proc. Natl. Acad. Sci. USA*, 74, 5463-5467, 1977) using single-strand DNA as a template for T7-DNA polymerase. The sequencing reaction and electrophoresis were carried out using an AutoRead DNA sequencing kit and a DNA

sequencer (Pharmacia). Single Strand DNA was prepared from *Escherichia coli* XL-Blue (Stratagene) after superinfection with helper phage R408 (Stratagene). The sequence data were analyzed with a computer using PC/Gene (Teijin System Technology).

To confirm the existence of the gene, Southern blot analysis was performed for chicken genomic DNA. Hybridization of the cDNA insert of pCRB3 for chicken genomic DNA gave a single band on digestion with EcoRI and two bands with BamHI. This simple hybridization pattern indicates that the cloned cDNA was a single copy gene. Southern blot analysis of genomic DNA from mouse and monkey with the pCRB3 probe under low stringency conditions suggested that this gene is conserved across species. For Southern blot, each 7.5 µg of genomic DNA prepared from mouse brain, COS-7 cells and chicken testes were digested with restriction enzyme and then size-fractionated on 0.6% agarose gels.

The mRNA size and distribution of the GalNAc $\alpha$ 2,6-sialyltransferase P-B3 gene were determined by Northern blot analysis. Analysis of RNA from 3, 6, 8, 10 and 12-day old embryos revealed two RNA species of 4.5 kb and 2.2 kb. The 4.5 kb mRNA was expressed abundantly at all embryonic stages examined, while not expressed in adult tissues. The less abundant 2.2 kb mRNA was expressed at the early embryonic stage, being abundant at the late embryonic stage and in adult tissues. The size of the 2.2-kb transcript suggests that the obtained cDNA clone ( $\lambda$ CEB3-T20) was close to full length. For Northern blots, 5 µg of poly(A)-rich RNAs from chick embryo and 10 µg of all RNA from chicken tissues were size-fractionated on formaldehyde-agarose gels.

Sialyltransferases previously known exhibit remarkable tissue-specific expression, which is considered to be correlated with the existence of cell type-specific carbohydrate structures (Paulson, J.C. and Colley, K.J., *J. Biol. Chem.*, 264, pp.17615-17618, 1989). The results of Northern blotting indicate that the pattern of expression of sialyltransferase P-B3 changes. The precise structure of embryo-specific 4.5 kb mRNA has not been known. However, the production of two different sizes of mRNAs from the sialyltransferase P-B3 gene suggests that they are very likely to be generated through alternative splicing and alternative promoter utilization mechanisms as observed for Gal $\beta$ 1,4GlcNAc- $\alpha$ 2,6-sialyltransferase (Gal $\beta$ 4GlcNAc- $\alpha$ 6STRL) and Gal $\beta$ 1,3(4)GlcNAc $\alpha$ 2,3-sialyltransferase (Gal $\beta$ 3(4)GlcNAc- $\alpha$ 3STRL) (Weinstein, J. et al., *J. Biol. Chem.*, 262, 17735-17743, 1987; and Wen, D.X. et al., *J. Biol. Chem.*, 267, 21011-21019, 1992). This hypothesis is supported by the results of Southern hybridization, which showed the existence of a single copy gene for sialyltransferase P-B3.

A 1.3 kb DNA fragment encoding the full length sialyltransferase P-B3 was amplified using synthetic oligonucleotide primers (5'-ACGGCGCTCGAGCCAAACCCGGAGAGCAGCG-3', and 5'-CGTTGC CTCGAGAGTCCTTGCAGTGGGACT-3', synthetic XhoI site underlined). The amplified DNA fragment was digested with XhoI and inserted into the XhoI site of the expression vector pcDSR $\alpha$  (Takebe, Y., *Mol. Cell. Biol.*, 8, pp.466-472, 1988) to yield recombinant plasmid pcDB3ST. The insert of the plasmid was sequenced to confirm the absence of possible polymerase chain reaction errors.

COS-7 cells were transfected with 5 µg of the recombinant plasmid pcDB3ST using the DEAE-dextran method (McCutchan, J.H. and Pagano, J.S., *J. Natl. Cancer Inst.*, 41, 351-357, 1968).

After 48 h of the transfection, the cultured cells ( $1 \times 10^7$ ) were harvested, washed with phosphate-buffered saline, and then resuspended in 2 ml of buffer comprising 20 mM MnCl<sub>2</sub> and 25 mM MES, pH 6.0. The cell suspension was centrifuged at 30,000  $\times$  g for 30 min, the cell pellet was resuspended in 0.5 ml or 1% Triton X-100, 50 mM NaCl, 5 mM MnCl<sub>2</sub>, 25 mM MES, pH 6.0, and then subjected to sonication. After centrifugation at 30,000  $\times$  g for 30 min, the supernatant was concentrated 10-fold on Centricon 30 filters (Amicon), and then used for following assays.

The enzyme assays with glycoproteins, oligosaccharides and glycolipids as acceptors were performed in the presence of 0.1 M sodium cacodylate buffer (pH 6.0), 10 mM MgCl<sub>2</sub>, 0.5% Triton CF54, 12 µM CMP-[<sup>14</sup>C]NeuAc (1.5 kBq), 1 mg/ml acceptor substrate, and 1 µl of COS cell lysate (in a final volume of 10 µl), with incubation at 37 °C for 1 hr. At the end of the incubation period, the reaction mixtures were subjected to SDS-PAGE for glycoproteins as acceptors, or were subjected to chromatography on HPTLC plates (Merck, Darmstadt, Germany) with a solvent system of ethanol/1-butanol/pyridine/acetic acid/water (100:10:10:3:30) for oligosaccharides and glycolipids as acceptors. Sialylated acceptors were quantified with a BAS2000 radio image analyzer (Fuji Photo Film, Japan).

Identifications of sialylated products were as follows. Reduced oligosaccharides were obtained from resialylated glycoproteins by  $\beta$ -elimination as described by Carlson (Carlson, D.M., *J. Biol. Chem.*, 243, pp.616-626, 1968). AsialoBSM was sialylated with CMP-[<sup>14</sup>C]NeuAc in a pcDB3ST-transfected COS-7 cell lysate under the same conditions as above. The radiolabeled oligosaccharides released from fetuin were digested with NDV sialidase, and then subjected to thin layer chromatography for identification of the products without further purification. Oligosaccharides released from BSM were used as standards. AsialoBSM and asialofetuin were [<sup>14</sup>C]-sialylated with the GalNAc $\alpha$ 2,6-sialyltransferase P-B1 and Gal $\beta$ 1,3GalNAc $\alpha$ 2,3-sialyltransferase (Lee, Y.-C., et al., *Eur. J. Biochem.*, 216, pp. 377-385, 1993), respectively, and the oligosaccharides were prepared by  $\beta$ -elimination. The resulting [<sup>14</sup>C]NeuAc $\alpha$ 2,6GalNAc-ol, Gal $\beta$ 1,3([<sup>14</sup>C]NeuAc $\alpha$ 2,6)GalNAc-ol and [<sup>14</sup>C]NeuAc $\alpha$ 2,3Gal $\beta$ 1,3GalNAc-ol were used as radio-labeled standards.

When fetuin was used as the acceptor, the acceptor was only sialylated by the lysate of COS-7 cells transfected with pcDB3ST. The expressed GalNAc $\alpha$ 2,6-sialyltransferase P-B3 exhibited strong activity toward fetuin and asialofetuin, and weak activity toward asialoBSM, whereas no significant activity was observed toward BSM or other glycopro-

teins having only N-glycosidically linked oligosaccharides (e.g.,  $\alpha$ 1-acid glycoprotein, ovomucoid, asialo- $\alpha$ 1 acid glycoprotein and asialo-ovomucoid) (Table 2).

In addition, oligosaccharides or glycosphingolipids could not serve as acceptors for the GalNAc $\alpha$ 2,6-sialyltransferase P-B3 of the present invention. [ $^{14}$ C]NeuAc residues incorporated into fetuin by the enzyme were resistant to treatment with N-glycanase or NDV sialidase. The radiolabelled oligosaccharides released from fetuin were co-migrated with Gal $\beta$ 1,3(NeuAc $\alpha$ 2,6)GalNAc-ol after treatment with NDV sialidase. These results indicate that sialic acid residues were transferred through  $\alpha$ 2,6-linkages on GalNAc residues of O-glycosidically linked oligosaccharides of fetuin. Thus, the expressed enzyme apparently has GalNAc $\alpha$ 2,6-sialyltransferase activity. However, asialoBSM was a much poorer acceptor than fetuin and asialofetuin for this GalNAc $\alpha$ 2,6-sialyltransferase P-B3 of the present invention. The acceptor substrate specificity is different from that of the GalNAc $\alpha$ 2,6-sialyltransferase P-B1 for which asialoBSM serves as a much better acceptor than asialofetuin.

To define the substrate specificity of the GalNAc $\alpha$ 2,6-sialyltransferase P-B3 of the present invention, fetuin was sequentially treated with sialidase (*Vibrio cholerae*) and  $\beta$ -galactosidase (bovine testes), and the resulting asialofetuin and agalacto-asialofetuin were used as acceptors. The incorporation of NeuAc-residues for the sialidase-treated fetuin was increased 1.5-fold of that for native fetuin. Three O-glycosidically linked oligosaccharides are known to be contained in fetuin, two of which are NeuAc $\alpha$ 2,3Gal $\beta$ 1,3GalNAc and the other is NeuAc $\alpha$ 2,3Gal $\beta$ 1,3(NeuAc $\alpha$ 2,6)-GalNAc (Spiro, R.G. and Bhoyroo, V. D., J. Biol. Chem., 249, 5704-5717, 1974). Accordingly, GalNAc residues in two of the three O-linked oligosaccharides can serve as acceptors in native fetuin, whereas those in all O-linked oligosaccharides in asialofetuin can be sialylated by the GalNAc $\alpha$ 2,6-sialyltransferase P-B3 of the present invention.

Furthermore, agalacto-asialofetuin could not serve as an acceptor of the GalNAc $\alpha$ 2,6-sialyltransferase P-B3 of the present invention, and only Gal $\beta$ 1,3([ $^{14}$ C]NeuAc $\alpha$ 2,6)GalNAc-ol, but not [ $^{14}$ C]NeuAc $\alpha$ 2,6-GalNAc-ol, was detected for the oligosaccharides released from asialoBSM incubated with the enzyme by  $\beta$ -elimination.

The characteristics of the GalNAc $\alpha$ 2,6-sialyltransferase P-B3 of the present invention revealed by the above experiments can be summarized as follows:

- (1-i) Fetuin and asialofetuin, which contain the O-glycosidically linked (NeuAc $\alpha$ 2,3)Gal $\beta$ 1,3GalNAc sequence (Spiro, R.G. and Bhoyroo, V.D., J. Bio. Chem., 249, 5704-5717, 1974), served as good acceptors, but asialoBSM, in which only 5% of the total carbohydrate chains contain Gal $\beta$ 1,3GalNAc sequences (Tsuji, T. and Osawa, T., Carbohydr. Res., 151, 391-402, 1986), served as a much poorer acceptor; and
- (1-ii) the protein portion is essential for the activity of this sialyltransferase, since Gal $\beta$ 1,3GalNAc $\alpha$ 1-Bz as well as asialoGM1 (Gal $\beta$ 1,3GalNAc $\beta$ 1,4Gal $\beta$ 1,3Glc $\beta$ 1-Cer) and GM1b (NeuAc $\alpha$ 2,3Gal $\beta$ 1,3GalNAc $\beta$ 1,4Gal $\beta$ 1,3Glc $\beta$ 1-Cer) did not serve as acceptors.
- (2) This sialyltransferase did not exhibit activity toward asialofetuin treated with  $\beta$ -galactosidase (agalacto-asialofetuin).
- (3) Only Gal $\beta$ 1,3([ $^{14}$ C]NeuAc- $\alpha$ 2,6)GalNAc-ol was detected in the oligosaccharides released from [ $^{14}$ C]sialylated asialoBSM although about 60% of the carbohydrate chains of asialoBSM are GalNAc-O-Ser/Thr (Tsuji, T. and Osawa, T., Carbohydr. Res., 151, 391-402, 1986).

These results clearly suggest that the acceptor substrate of the enzyme of the present invention having catalytic activity, i.e., transfer of CMP-NeuAc with an  $\alpha$ 2,6-linkage onto a GalNAc residue O-linked to Thr/Ser of a glycoprotein, requires Gal $\beta$ 1,3 GalNAc sequence of O-glycoside linked oligosaccharide, whereas  $\alpha$ 2,3 linkage-sialic acid residues linked to galactose residues are not essential for the activity. Therefore, the enzyme P-B3 first cloned by the present invention is a novel type of GalNAc $\alpha$ 2,6-sialyltransferase. The primary sequence of GalNAc $\alpha$ 2,6-sialyltransferase P-B3 from the 45 amino acid regions at the molecular center (sialylmotif L) to the COOH-terminal (residues: 180-404) exhibits high sequence homology to that of GalNAc $\alpha$ 2,6-sialyltransferase P-B1 (Fig. 4: the identity is 48%). The conserved regions unique to these GalNAc $\alpha$ 2,6-sialyltransferases may be correlated with their enzymatic function of transferring sialic acid to the GalNAc-moiety via an  $\alpha$ 2,6-linkage.

Table 2

Acceptor substrate specificity of GalNAc $\alpha$ 2,6-sialyltransferase P-B3 of the invention	
Acceptor	Specificity
	pmol/h/ $\mu$ l enzyme fraction
Fetuin	28
Asialofetuin	35
BSM	0.5
AsialoBSM	5.2
$\alpha$ 1-Acid glycoprotein	0
Asialo- $\alpha$ 1-acid glycoprotein	1.2
Ovomucoid	0
Asialo-ovomucoid	1.0
Gal $\beta$ 1,3GalNAc $\alpha$ 1-Bz	0
GalNAc $\alpha$ 1-Bz	0
GalNAc-SerNAc	0
AsialoGM1	0
GM1b	0
Ganglioside Mixture	0
0 indicates less than 0.5 pmol/h.	

The reagents, samples and the like used in the above preparation example (C) were as follows. Fetuin, asialofetuin, bovine submaxillary mucin,  $\alpha$ 1-acid glycoprotein, galactose  $\beta$ 1,4-N-acetylgalactosamine, CMP-NeuAc, Gal $\beta$ 1,3GalNAc $\alpha$ 1-Bz, GalNAc $\alpha$ 1-Bz and Triton CF-54 were obtained from Sigma (St. Louis, USA). CMP-[ $^{14}$ C]NeuAc (11 GBq/mmol) was obtained from Amersham (U.K.). 2-Acetamide and 2-deoxygalactosyl $\alpha$ N-acetyls erine (GalNAc-SerNAc) was synthesized according to Grundler and Schmidt (Grunder G., and Schmidt R.R., Liebigs Ann. Chem., 1984, 1826-1847, 1984). NDV-sialidase and sialidase from *Vibrio cholerae* were purchased from Oxford Glycosystems (U.K.) and Boehringer Mannheim (Germany), respectively. p-Galactosidase from bovine testes was obtained from Boehringer Mannheim (Germany). Synthetic primers were synthesized with the Applied Biosystem 394 DNA synthesizer. Restriction endonucleases were obtained from Takara (Japan)

#### (D) Purification of sialyltransferase expressed in microorganisms

##### Plasmid construction

An initiation codon and cloning sites were attached by PCR to mouse Gal $\beta$ 1,4GlcNAc $\alpha$ 2,6-Sialyltransferase cDNA (Hamamoto, T. et al., Bioorg. Medicin. Chem., 1, 141-145, 1993). 5'-TGGCATATGGGGAGCG ACTATGAGGCTCT-3' containing an NdeI site was used as a sense primer and 5'-ATGAGGATCCCTGGCTCAACAGCG-3' containing a BamHI site as an antisense primer. The resulting PCR fragment (1152 bp) contained the initiation codon and a region coding for a polypeptide from the 29th amino acid residue to the C-terminal end of the enzyme, and lacked the cytosolic and transmembrane domains. The fragment was incorporated into expression vector pET3b (Studier, F.W. et al., Method. Enzymol., 185, 60-89, 1990) at the NdeI-BamHI site (located downstream of the T7 promoter). The resulting recombinant vector was named as pET3-MBS. The nucleotide sequence of the PCR fragment is shown as the SEQ ID No.4 in the sequence listings.



## Enzyme expression

*E. coli* JM109(DE3) cells transfected with the vector pET3-MBS were cultured in 100 ml LB medium supplemented with 100 µg/ml ampicillin at 37 °C. When the optical density at 600 nm reached 0.2-0.4, production of the recombinant protein was initiated with induction of T7 RNA polymerase by the addition of 2 mM IPTG (isopropylβ-D-thiogalactopyranoside). The recombinant enzyme, lacking the cytosolic and the transmembrane domain, was accumulated in the form of insoluble inclusion bodies in the cells. The growth rate of the JM109(DE3) cells transfected with pET3-MBS was the same as that of the non-transfected JM109(DE3) cells both on agar plates and in liquid culture. After 2 h cultivation, the cells were harvested (ca. 1 g wet weight), suspended in 10 ml of 20 mM Tris-HCl (pH 8.0), and then treated with lysozyme (0.1 mg/ml) and DNase I (0.01 mg/ml) for 30 min. Triton X-100 was added to a final concentration of 1%, and insoluble fraction was collected by centrifugation at 12,000 × g for 15 min at 4 °C. The precipitate was suspended in 3 ml of 10 mM Tris-HCl (pH 7.4) and stored at -30°C before use.

## Solubilization and renaturation

To 0.5 ml of the above suspension, 0.48 g solid urea, 60 µl of 5 M NaCl, 20 µl of 1 M Tris-HCl (pH 7.4) and water were added to final volume of 1 ml (final concentration: 8 M urea, 0.3 M NaCl; 20 mM Tris-HCl, pH 7.4). The precipitate was extracted for 30 min at 10°C, followed by centrifugation at 12,000 × g for 15 min. Most of the extracted protein had the molecular mass of 42k dalton. Where 5.7 M urea buffer was used for the extraction, 80% of the enzyme was recovered.

The 0.1 ml aliquots of extract containing 8 M urea were diluted with each 1.9 ml of a renaturation composition (standard composition: 2 M urea, 0.5 M NaCl, 10 mM lactose, 0.5 mM EDTA, and 20 mM MOPS-NaOH, pH 7.0) to a final protein concentration of about 0.02 mg/ml. The solution was left at 40°C for 12 h, and then diluted again with an equal volume of the renaturation composition, thereby reducing the urea concentration to half (approximately 1.2 M), and then the mixture was left at 40 °C for additional 48 h. Then, sialyltransferase activity was measured to analyze the effects of the components of the renaturation composition at this point (Table 3). The resulting enzymes were further dialyzed against the renaturation composition to remove residual urea and the reducing agents over 48 h at 4 °C. The samples were concentrated approximately 20 times with Centricon-30 (Amicon).

## Sialyltransferase assay

The activity of the sialyltransferase was measured with 50 µM CMP-[<sup>14</sup>C]NeuAc (0.9 Bq/pmole) as a donor substrate, and 5 mM Galβ1,4GlcNAc (N-acetyllactosamine) as an acceptor substrate. Reaction mixture was added with 1 mg/ml bovine serum albumin, 1 µl of the enzyme solution, and 50 mM sodium cacodylate (pH 6.0) to a total volume of 10 µl, and incubation was continued at 37 °C for 1 h. Then, the samples were applied to silica gel60 HPTLC plate (Merck Germany) and developed with ethanol/pyridine/n-butanol/acetic acid/water (100:10:10:3:30) as a developing solvent. The radioactivity transferred on each plate was determined with a radio image analyzer BAS2000 (Fuji Photo Film, Japan, Lee, Y.-C. et al., Eur. J. Biochem., 216, 377-385, 1993). One unit of enzymatic activity was defined as an amount catalyzing 1 µmole of sialic acid transfer per minute. The acceptor preference as to oligosaccharide branches was examined using a N-acetyllactosamine type biantennary pyridylamino-oligosaccharide as an acceptor substrate and analyzed fluorophotometrically by HPLC.

When the 8 M urea extract was dialyzed without dilution at 4 °C, almost no activity of the enzyme precipitated at concentration of less than 0.5 M was recovered. The results of the optimum dilution conditions at 48 h after the second dilution are shown in Table 3 set out below. In the table, the standard renaturation composition was comprised of: 2 M urea, 20 mM Tris-HCl, 0.3 M NaCl, 20 mM lactose, and 0.5 mM EDTA (pH 7.4), and as to other compositions, deviations from the standard composition are indicated.

Table 3

The effects of various conditions on renaturation of Gal $\beta$ 1,4GalNAc $\alpha$ 2,6-sialyltransferase	
Renaturation conditions	Relative activity compared to standard
Standard composition	1
pH 9.5, Tris-HCl 20 mM	0*
pH 8.0, Tris-HCl 20 mM	0.6
pH 7.0, MOPS-NaOH 20 mM	2.5
pH 6.0, MES-NaOH 20 mM	1.5
0.5 M NaCl	2
0.1 M NaCl	0.2
0.01 M NaCl	0
0 mM lactose	0.5
1 M urea	1.5
0 M urea	0.6

\* A value of 0 indicates less than 5% of the control.

The maximum renaturation was observed with 0.5 M NaCl (pH 7.0) in the standard composition, and these compositions were used in further experiments. After three independent renaturation experiments were carried out under this condition, total recovered activities were 0.4-0.8 mU/0.1 ml extract. The enzymes at this stage of renaturation showed high  $K_m$  values for CMP-NeuAc and N acetyllactosamine, 0.14 mM and 20 mM, respectively. Under the conditions tested, reducing agents (DTT and  $\beta$ -mercaptoethanol) inhibited the enzyme activity, which may be due to carryover of urea at the concentration of 0.1 M in the assay mixture. In addition, very little activity was observed at 12 h after the second dilution, which apparently indicates that a refolding process of the polypeptide is very slow at the test temperature. Almost the same activity, as that in the process without the use of the reducing reagents, was obtained by the following process: the 8 M urea extract was diluted with 20 volumes of the renaturation composition containing 2 M urea, 20 mM MOPS-NaOH, pH 7.0, 0.5 M NaCl, 20 mM lactose, and 0.5 mM EDTA in the presence of 1  $\mu$ M or 1 mM reducing reagents, and then samples were left at 4 °C for 12 h and diluted to reduce the urea concentration to half, and the residual urea and reducing reagents were removed by dialysis. The results are shown in Table 4.

Table 4

Reducing reagent	Specific activity (mU/mg)
None	7
1 $\mu$ M DTT	6
1 mM DTT	12

The substrate specificity of renatured mouse Gal $\beta$ 1,4GlcNAc $\alpha$ 2,6-sialyltransferase was assayed using each 2 mg/ml of substrates. The products were analyzed by HPTLC. HPTLC was performed using ethanol/pyridine/n-butanol/acetic acid/water (100:10:10:3:30) as a developing solvent when oligosaccharides and glycoproteins were used as acceptors, and chloroform:methanol:0.5%  $\text{CaCl}_2$  (55:45:8) as a developing solvent when glycolipids were used as acceptors. The substrate specificity and kinetic parameters of the renatured enzymes were similar to those of the enzyme obtained from rat liver.

The results are shown in Table 5 and Table 6.

Table 5

Substrate	Relative Activity to Gal $\beta$ 1,4GlcNAc	
	Renatured mouse Gal $\beta$ 1,4GlcNAc $\alpha$ 2,6-sia- lyltransferase	Rat liver Gal $\beta$ 1,4GlcNAc $\alpha$ 2,6-sia- lyltransferase
Fetuin	0.25	0*
Asialofetuin	1.5	0.97
$\alpha$ 1 acid glycoprotein	0.1	0.1
Asialo- $\alpha$ 1 acid glycoprotein	2.1	1
Bovine submaxillary mucin	0	0
Bovine submaxillary asialo-mucin	0	0
Lacto N-tetraose	0	0
Gal $\beta$ 1,4GlcNAc	1	1
Gal $\beta$ 1,3GlcNAc	0	0
GalNAc $\beta$ 1,4Gal	0	0
Gal $\beta$ 1,4Glc	0	0
Gal	0	0

\* A value of 0 indicates less than 2% of the control.

Table 6

Substrate	Km (mM)	
	Renatured mouse Gal $\beta$ 1,4GlcNAc $\alpha$ 2,6-sia- lyltransferase	Rat liver Gal $\beta$ 1,4GlcNAc $\alpha$ 2,6-sia- lyltransferase
CMP-NeuAc*	0.08	0.04
N-acetyllactosamine	6.5	5
Asialo-orosomucoid**	0.4	0.2

\* Measured with N-acetyllactosamine as the acceptor.

\*\* Concentration expressed as terminal galactose residues.

Gal $\beta$ 1,4GlcNAc $\alpha$ 2,6-sialyltransferase is capable of recognizing the different branches of biantennary glycopeptides of the N-acetyllactosamine type (Joziasse, D.H. et al., J. Biol. Chem., 260, 714-719, 1985; and Van den Eijnden D.H. et al., Biochem. Biophys. Res. Comm., 92, 839-845, 1980). A desialylated biantennary PA-oligosaccharide was sialylated by the enzyme renatured according to the method of the present invention and then analyzed with HPLC. The assays were performed using 10 pmoles of acceptor substrates and 0.1 mM CMP-NeuAc in a final volume of 5  $\mu$ l. The reaction mixtures were incubated at 37°C for 1 h, and the reaction was stopped by the addition of 90  $\mu$ l of cold water. To identify sialylated pyridylamino oligosaccharides, each reaction mixture was subjected to HPLC analyses equipped with a reversed-phase column (Shimpack CLC-ODS, 0.6 cm  $\times$  15 cm, Shimazu, Japan). The column was equilibrated with mixture of 70% solvent A (10 mM sodium phosphate, pH 3.8) and 30% solvent B (0.5% n-butanol, 10 mM sodium phosphate, pH 3.8), and eluted at the flow rate of 1 ml/min with a linear gradient of solvent B to 60% over 30 min at 55°C. Pyridylamino oligosaccharides were detected fluorophotometrically (excitation at 320 nm and emission at 400 nm), and

the results indicated that the renatured enzyme showed higher preference for galactose residues on Man $\alpha$ 1,3 branches rather than for galactose residues on Man $\alpha$ 1,6 branches like the native enzyme.

By completely remove urea, the renatured enzyme restored its resistance to reducing agents. In addition, more than 10 times activation was recovered by renaturing with the addition of divalent cations. While not bound by any specific theory, where dialysis is carried out for a prolonged period of time against a dialysis buffer containing 0.5 mM EDTA in the presence of urea, divalent cations, which are tightly bound to the enzyme to maintain the proper conformation of the enzyme, may be lost. Where the enzyme was renatured in the renaturation composition containing 1.2 M urea, the addition of divalent cations increased the activity. The results obtained are shown in Table 7. In the table, the activities are shown as relative values to that obtained by no addition of reagents. The specific activity of the renatured enzyme was 0.15 U/mg protein when measured with 5 mM MnCl<sub>2</sub>, which is about 2% of that of the enzyme obtained from rat liver (weinstein, J. et al., J. Biol. Chem., 257, pp.13835-13844, 1982). The overall recovery of the enzyme was 0.1 U/100 ml culture medium.

Table 7

Reagent	Renatured mouse Gal $\beta$ 1,4GlcNAc $\alpha$ 2,6- sialyltransferase	Rat liver Gal $\beta$ 1,4GlcNAc $\alpha$ 2,6- sialyltransferase
Reducing agent		
DTT (1 mM)	1.0	0.9
(1 $\mu$ M)	1.1	1.2
Mercaptoethanol (1 mM)	1.1	1.1
(1 $\mu$ M)	1.0	1.1
Detergent		
Triton x-100 (1%)	1.5	0.8
(0.5%)	1.4	1.4
(0.1%)	1.3	1.3
Divalent cations		
MgCl <sub>2</sub> (5 mM)	11	1.0
MnCl <sub>2</sub> (5 mM)	13	1.1
EDTA (5 mM)	1.7	0.9

The method of the present invention was specifically explained above referring to the examples relating to the Gal $\beta$ 1,4GlcNAc $\alpha$ 2,6-sialyltransferase. However, the method of the present invention is not limited to these examples. As described above, unlike other glycosyltransferases, sialyltransferases share highly conserved regions (sialylmotif, Livingston, B.D. and Paulson, J.C., J. Biol. Chem., 268, 11504-11507, 1993), and all of the sialyltransferases are considered to have similar higher-order structures (Drickamer, K., Glycobiology, 3, 2-3, 1993). Therefore, it is readily understood by those skilled in the art that the renaturation procedure disclosed in the above examples for Gal $\beta$ 1,4GlcNAc $\alpha$ 2,6-sialyltransferase can be applied to renaturations of other sialyltransferases to achieve the same advantageous effects. Furthermore, those skilled in the art will be able to choose optimum renaturing conditions, not only for Gal $\beta$ 1,4GlcNAc $\alpha$ 2,6-sialyltransferase but for other sialyltransferases, by modifying or altering the processes disclosed in the specification.

The reagents and samples used in the above example (D) were as follows. Rat liver Gal $\beta$ 1,4GlcNAc $\alpha$ 2,6-sialyltransferase, fetuin, asialo-fetuin, bovine submaxillary mucin,  $\alpha$ 1-acid glycoprotein, galactose  $\beta$ 1,3-N-acetylgalactosamine, lacto N-tetraose and N-acetyllactosamine were obtained from Sigma (St. Louis, USA). Urea was purchased from Wako Pure Chemicals (Osaka, Japan) and a solution was prepared just before use. CMP-[<sup>14</sup>C]NeuAc (11 GBq/mmol) was obtained from Amersham (U.K). Bovine submaxillary asialo-mucin and asialo- $\alpha$ 1-acid glycoprotein were obtained by mild acid treatment of corresponding glycoproteins. N-acetylgalactosamine  $\beta$ 1,4-galactose was a kind gift from Dr. Kajimoto (The institute of Physical and Chemical Research, RIKEN, Wako-shi, Saitama-ken, Japan). Pyridylamino oligosaccharides (PA-sugar 001, 021, 022 and 023) were obtained from Takara (Kyoto, Japan). Protein concentrations

were determined with a BCA protein assay kit (Pierce) using bovine serum albumin as the standard. Dialysis tubing (20/32) was from Viskase.

#### Industrial applicability

5           The novel GalNAc $\alpha$ 2,6-sialyltransferases P-B1 and P-B3, and proteins which contain a polypeptide part as being the active domain of said enzymes and are released extracellularly provided by the present invention are useful as, for example, reagents for introducing human type sugar-chain to proteins and medicament for treating hereditary diseases lacking human-specific sugar chains. In addition, they can be used as drugs for inhibiting tumor metastases, preventing  
10       viral infection, and controlling inflammatory reaction. Furthermore, the method of the present invention is useful when a large quantity of a sialyltransferase is expressed in microorganisms, since it enables a mass recovery of the enzyme with highly restored activity from aggregate or precipitate inside the cells.

15

20

25

30

35

40

45

50

55

# EP 0 737 745 A1

## SEQUENCE LISTING

5

(2) INFORMATION OF SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2027

10

(B) TYPE: nucleic acid

(C) STRANDNESS: double

(D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: cDNA to mRNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

20

(-31) CCGAGCTTCCATCTCTCCCGGGCCTCTCACT -1

25

ATG GGG TTT TTA ATC AGA AGG CTT CCT AAA GAT TCC AGA ATA TTC	45
MET Gly Phe Leu Ile Arg Arg Leu Pro Lys Asp Ser Arg Ile Phe	15

30

CGT TGG CTC CTT ATT TTA ACA GTC TTT TCC TTC ATC ATT ACT AGT	90
Arg Trp Leu Leu Ile Leu Thr Val Phe Ser Phe Ile Ile Thr Ser	30

35

TTT AGC GCC TTG TTT GGC ATG GAG AAA AGC ATT TTC AGG CAG CTC	135
Phe Ser Ala Leu Phe Gly MET Glu Lys Ser Ile Phe Arg Gln Leu	45

40

AAG ATT TAC CAA AGC ATT GCA CAT ATG CTA CAA GTG GAC ACC CAA	180
Lys Ile Tyr Gln Ser Ile Ala His MET Leu Gln Val Asp Thr Gln	60

45

GAT CAG CAA GGT TCA AAC TAT TCT GCT AAT GGG AGA ATT TCA AAG	225
Asp Gln Gln Gly Ser Asn Tyr Ser Ala Asn Gly Arg Ile Ser Lys	75

50

GTT GGT TTG GAG AGA GAC ATT GCA TGG CTC GAA CTG AAT ACT GCT	270
Val Gly Leu Glu Arg Asp Ile Ala Trp Leu Glu Leu Asn Thr Ala	90

55

# EP 0 737 745 A1

	GTG AGT ACA CCA AGT GGG GAA GGG AAG GAA GAG CAG AAG AAA ACA	315
5	Val Ser Thr Pro Ser Gly Glu Gly Lys Glu Glu Gln Lys Lys Thr	105
	GTG AAA CCA GTT GCC AAG GTG GAA GAA GCC AAG GAG AAA GTG ACT	360
10	Val Lys Pro Val Ala Lys Val Glu Glu Ala Lys Glu Lys Val Thr	120
	GTG AAA CCA TTC CCT GAG GTG ATG GGG ATC ACA AAT ACA ACA GCA	405
15	Val Lys Pro Phe Pro Glu Val MET Gly Ile Thr Asn Thr Thr Ala	135
	TCA ACA GCC TCT GTG GTG GAG AGA ACA AAG GAG AAA ACA ACA GCG	450
20	Ser Thr Ala Ser Val Val Glu Arg Thr Lys Glu Lys Thr Thr Ala	150
	AGA CCA GTT CCA GGG GTG GGG GAA GCT GAT GGG AAG AGA ACA ACG	495
25	Arg Pro Val Pro Gly Val Gly Glu Ala Asp Gly Lys Arg Thr Thr	165
	ATA GCA CTT CCC AGC ATG AAG GAA GAC AAA GAG AAG GCG ACT GTG	540
30	Ile Ala Leu Pro Ser MET Lys Glu Asp Lys Glu Lys Ala Thr Val	180
	AAA CCA TCC TTT GGG ATG AAG GTA GCT CAT GCA AAC AGC ACA TCC	585
35	Lys Pro Ser Phe Gly MET Lys Val Ala His Ala Asn Ser Thr Ser	195
	AAA GAT AAA CCA AAG GCA GAA GAG CCT CCT GCA TCA GTG AAA GCC	630
40	Lys Asp Lys Pro Lys Ala Glu Glu Pro Pro Ala Ser Val Lys Ala	210
	ATA AGA CCT GTG ACT CAG GCT GCC ACA GTG ACA GAG AAG AAG AAA	675
45	Ile Arg Pro Val Thr Gln Ala Ala Thr Val Thr Glu Lys Lys Lys	225
	CTG AGG GCT GCT GAC TTC AAG ACT GAG CCA CAG TGG GAT TTT GAT	720
50	Leu Arg Ala Ala Asp Phe Lys Thr Glu Pro Gln Trp Asp Phe Asp	240
55		

# EP 0 737 745 A1

	GAT GAG TAC ATA CTG GAT AGC TCA TCT CCA GTA TCG ACC TGC TCT	765
5	Asp Glu Tyr Ile Leu Asp Ser Ser Ser Pro Val Ser Thr Cys Ser	255
	GAA TCA GTG AGA GCC AAG GCT GCC AAG TCT GAC TGG CTG CGA GAT	810
10	Glu Ser Val Arg Ala Lys Ala Ala Lys Ser Asp Trp Leu Arg Asp	270
	CTT TTC CTG CCG AAC ATC ACA CTC TTC ATA GAC AAG AGT TAC TTC	855
15	Leu Phe Leu Pro Asn Ile Thr Leu Phe Ile Asp Lys Ser Tyr Phe	285
	AAT GTC AGT GAG TGG GAC CGC CTG GAG CAT TTT GCA CCT CCC TAT	900
20	Asn Val Ser Glu Trp Asp Arg Leu Glu His Phe Ala Pro Pro Tyr	300
	GGC TTC ATG GAG CTG AAT TAC TCA CTG GTA GAA GAA GTC ATG TCA	945
25	Gly Phe MET Glu Leu Asn Tyr Ser Leu Val Glu Glu Val MET Ser	315
	CGG CTG CCT CCA AAT CCC CAC CAG CAG CTG CTC CTG GCC AAC AGT	990
30	Arg Leu Pro Pro Asn Pro His Gln Gln Leu Leu Leu Ala Asn Ser	330
	AGC AGC AAC GTG TCA ACG TGC ATC AGC TGT GCT GTT GTG GGG AAT	1035
35	Ser Ser Asn Val Ser Thr Cys Ile Ser Cys Ala Val Val Gly Asn	345
	GGA GGG ATA TTG AAT AAC TCT GGA ATG GGC CAG GAG ATT GAC TCC	1080
40	Gly Gly Ile Leu Asn Asn Ser Gly MET Gly Gln Glu Ile Asp Ser	360
	CAT GAC TAT GTG TTC CGG GTG AGC GGG GCT GTA ATC AAA GGT TAC	1125
45	His Asp Tyr Val Phe Arg Val Ser Gly Ala Val Ile Lys Gly Tyr	375
	GAA AAG GAT GTG GGA ACA AAA ACC TCC TTC TAC GGA TTC ACA GCG	1170
50	Glu Lys Asp Val Gly Thr Lys Thr Ser Phe Tyr Gly Phe Thr Ala	390
55		



# EP 0 737 745 A1

	TAC TCC CTG GTG TCC TCT CTC CAG AAC TTG GGA CAC AAA GGG TTC	1215
5	Tyr Ser Leu Val Ser Ser Leu Gln Asn Leu Gly His Lys Gly Ph	405
	AAG AAG ATC CCA CAG GGG AAG CAT ATC AGA TAC ATT CAC TTC CTG	1260
10	Lys Lys Ile Pro Gln Gly Lys His Ile Arg Tyr Ile His Phe Leu	420
	GAG GCA GTT AGA GAC TAT GAG TGG CTG AAG GCT CTT CTG TTG GAC	1305
15	Glu Ala Val Arg Asp Tyr Glu Trp Leu Lys Ala Leu Leu Leu Asp	435
	AAG GAT ATC AGG AAA GGA TTC CTG AAC TAC TAT GGG CGA AGG CCC	1350
20	Lys Asp Ile Arg Lys Gly Phe Leu Asn Tyr Tyr Gly Arg Arg Pro	450
	CGG GAG AGA TTC GAT GAA GAT TTC ACA ATG AAT AAG TAC CTG GTA	1395
25	Arg Glu Arg Phe Asp Glu Asp Phe Thr MET Asn Lys Tyr Leu Val	465
	GCT CAC CCT GAT TTC CTC AGA TAC TTG AAA AAC AGG TTC TTA AAA	1440
30	Ala His Pro Asp Phe Leu Arg Tyr Leu Lys Asn Arg Phe Leu Lys	480
	TCT AAA AAT CTG CAA AAG CCC TAC TGG CGG CTG TAC AGA CCC ACA	1485
35	Ser Lys Asn Leu Gln Lys Pro Tyr Trp Arg Leu Tyr Arg Pro Thr	495
	ACA GGA GCC CTC CTG CTG CTG ACT GCC CTG CAT CTC TGT GAC CGG	1530
40	Thr Gly Ala Leu Leu Leu Leu Thr Ala Leu His Leu Cys Asp Arg	510
	GTG AGT GCC TAT GGC TAC ATC ACA GAA GGT CAC CAG AAG TAC TCG	1575
45	Val Ser Ala Tyr Gly Tyr Ile Thr Glu Gly His Gln Lys Tyr Ser	525
	GAT CAC TAC TAT GAC AAG GAG TGG AAA CGC CTG GTC TTC TAC GTT	1620
50	Asp His Tyr Tyr Asp Lys Glu Trp Lys Arg Leu Val Phe Tyr Val	540
55		

# EP 0 737 745 A1

	AAC CAT GAC TTC AAC TTG GAG AAG CAG GTG TGG AAA AGG CTT CAT	1665
5	Asn His Asp Phe Asn Leu Glu Lys Gln Val Trp Lys Arg Leu His	555
	GAT GAG AAC ATC ATG AAG CTC TAC CAG AGA TCC TGA CAG TGT GCC	1710
10	Asp Glu Asn Ile MET Lys Leu Tyr Gln Arg Ser ---	566
	GAGGGCCATT GCCTGGGAAA TCTCAACAGC ACCTCATGGG GAACAGAAGA	1760
15	GGACCTCGGA AGCCAGGGTT AGCTCTGGAC TTCCAGGCCC AGCTTCAGCT	1810
	CCACAGAGAT ATTTCCCTCC TTTGATATCT TTATTTTCTC ACAACACTTC	1860
	CTAAAATGTG CATATTCTAC AGACCAAGCG AACAGTAGGG AAAAGTGCCT	1910
20	CCTAACCAAGG TCCCATCTGA CTTGTGGACG GTTGTAGGCT CTGGTACTGG	1960
	GAAAGAGGAA TCCGGGATGA ATCCGAATAG CAGATGTTCC AGTGCCCAT	2010
	ATCTTAATCA GGTCTCCCT CTGCAAGGAG ATGCTCTTGG GGCTGGGGCT	2060
25	AGTTTTGCTC TAGGTGGGTT CTCTCTGTGA GTAGTGCTTG TTATGGAGCT	2110
	GGGTGTTTTG GGTAAGCAGT GGATAGAATG GAGACACACA CAATCCTGTC	2160
	TCAAGAGGAT GATTGTGTG CTGGAGGTGC TGCTGTCACT CTGCTCACTG	2210
30	CAGGCATAAG GACCCTTCCA ATGAACTCAA TCCCAATGTG ACTTTGCTGT	2260
	GACACCTCCT GGGGAGCACT GTGATGTCGG TGCCAGCCT GCTGCCCTTG	2310
	GCCTAGTTCA CCATCAGCAC AAGGGAAGGG GAGAGCCCTC CGTAGTCAG	2360
35	CAGAATGCTG GACATTGTAC CTCTTGCTGT GGGTTCCCCT GGCTGCAGAC	2410
	TACGTGTAGT GAGTCTGATG AAGAAGCTGG TGCTTGGCTG TGCCAGGAGC	2460
	ATGGTGCTTC CTCTTCTACC AGGAGAAATG AGAATTCTCA ATGTCCATGG	2510
40	ATGGATGCTG TCTGTCCTTG CTGCTGGCTG GAGTGCCTGC CTACATTGTC	2560
	CTGAGAAAAG CACTGTTACA GCCAGTAAGC CTTTGGAGTA TTGGCCTTCT	2610
	GAGTGGGCTT TTGCAAACAA AATAAACGGC ACTGCTTTCC CCCAAGCTGA	2660
45	AAAAAAAAA A	2671

(2) INFORMATION OF SEQ ID NO:2:

50 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1294

55

# EP 0 737 745 A1

(B) TYPE: nucleic acid

(C) STRANDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

(-43) CTG CAGGGTTTTT ATTTTAAATT TTCTTCAAA TACTTCCACC -1

PstI

ATG AAA TTC AGC TGG GTC ATG TTC TTC CTG ATG GCA GTG GTT ACA 45

MET Lys Phe Ser Trp Val MET Phe Phe Leu MET Ala Val Val Thr 15

GGG GTC AAT TCA GAA TTC ACT GAG CCA CAG TGG GAT TTT GAT GAT 90

Gly Val Asn Ser Glu Phe Thr Glu Pro Gln Trp Asp Phe Asp Asp 30

GAG TAC ATA CTG GAT AGC TCA TCT CCA GTA TCG ACC TGC TCT GAA 135

Glu Tyr Ile Leu Asp Ser Ser Ser Pro Val Ser Thr Cys Ser Glu 45

TCA GTG AGA GCC AAG GCT GCC AAG TCT GAC TGG CTG CGA GAT CTT 180

Ser Val Arg Ala Lys Ala Ala Lys Ser Asp Trp Leu Arg Asp Leu 60

TTC CTG CCG AAC ATC ACA CTC TTC ATA GAC AAG AGT TAC TTC AAT 225

Phe Leu Pro Asn Ile Thr Leu Phe Ile Asp Lys Ser Tyr Phe Asn 75

GTC AGT GAG TGG GAC CGC CTG GAG CAT TTT GCA CCT CCC TAT GGC 270

Val Ser Glu Trp Asp Arg Leu Glu His Phe Ala Pro Pro Tyr Gly 90

60

70

TTC ATG GAG CTG AAT TAC TCA CTG GTA GAA GAA GTC ATG TCA CGG 315

Phe MET Glu Leu Asn Tyr Ser Leu Val Glu Glu Val MET Ser Arg 105

# EP 0 737 745 A1

	CTG CCT CCA AAT CCC CAC CAG CAG CTG CTC CTG GCC AAC AGT AGC	360
5	Leu Pro Pro Asn Pro His Gln Gln Leu Leu Leu Ala Asn Ser Ser	120
	AGC AAC GTG TCA ACG TGC ATC AGC TGT GCT GTT GTG GGG AAT GGA	405
10	Ser Asn Val Ser Thr Cys Ile Ser Cys Ala Val Val Gly Asn Gly	135
	GGG ATA TTG AAT AAC TCT GGA ATG GGC CAG GAG ATT GAC TCC CAT	450
15	Gly Ile Leu Asn Asn Ser Gly MET Gly Gln Glu Ile Asp Ser His	150
	GAC TAT GTG TTC CGG GTG AGC GGG GCT GTA ATC AAA GGT TAC GAA	495
20	Asp Tyr Val Phe Arg Val Ser Gly Ala Val Ile Lys Gly Tyr Glu	165
	AAG GAT GTG GGA ACA AAA ACC TCC TTC TAC GGA TTC ACA GCG TAC	540
25	Lys Asp Val Gly Thr Lys Thr Ser Phe Tyr Gly Phe Thr Ala Tyr	180
	TCC CTG GTG TCC TCT CTC CAG AAC TTG GGA CAC AAA GGG TTC AAG	585
30	Ser Leu Val Ser Ser Leu Gln Asn Leu Gly His Lys Gly Phe Lys	195
	AAG ATC CCA CAG GGG AAG CAT ATC AGA TAC ATT CAC TTC CTG GAG	630
35	Lys Ile Pro Gln Gly Lys His Ile Arg Tyr Ile His Phe Leu Glu	210
	GCA GTT AGA GAC TAT GAG TGG CTG AAG GCT CTT CTG TTG GAC AAG	675
40	Ala Val Arg Asp Tyr Glu Trp Leu Lys Ala Leu Leu Leu Asp Lys	225
	GAT ATC AGG AAA GGA TTC CTG AAC TAC TAT GGG CGA AGG CCC CGG	720
45	Asp Ile Arg Lys Gly Phe Leu Asn Tyr Tyr Gly Arg Arg Pro Arg	240
	GAG AGA TTC GAT GAA GAT TTC ACA ATG AAT AAG TAC CTG GTA GCT	765
50	Glu Arg Phe Asp Glu Asp Phe Thr MET Asn Lys Tyr Leu Val Ala	255
55		

# EP 0 737 745 A1

	CAC CCT GAT TTC CTC AGA TAC TTG AAA AAC AGG TTC TTA AAA TCT	810
5	His Pro Asp Phe Leu Arg Tyr Leu Lys Asn Arg Phe Leu Lys Ser	270
	AAA AAT CTG CAA AAG CCC TAC TGG CGG CTG TAC AGA CCC ACA ACA	855
10	Lys Asn Leu Gln Lys Pro Tyr Trp Arg Leu Tyr Arg Pro Thr Thr	285
	GGA GCC CTC CTG CTG CTG ACT GCC CTG CAT CTC TGT GAC CGG GTG	900
15	Gly Ala Leu Leu Leu Leu Thr Ala Leu His Leu Cys Asp Arg Val	300
	AGT GCC TAT GGC TAC ATC ACA GAA GGT CAC CAG AAG TAC TCG GAT	945
20	Ser Ala Tyr Gly Tyr Ile Thr Glu Gly His Gln Lys Tyr Ser Asp	315
	CAC TAC TAT GAC AAG GAG TGG AAA CGC CTG GTC TTC TAC GTT AAC	990
25	His Tyr Tyr Asp Lys Glu Trp Lys Arg Leu Val Phe Tyr Val Asn	330
	CAT GAC TTC AAC TTG GAG AAG CAG GTG TGG AAA AGG CTT CAT GAT	1035
30	His Asp Phe Asn Leu Glu Lys Gln Val Trp Lys Arg Leu His Asp	345
	GAG AAC ATC ATG AAG CTC TAC CAG AGA TCC TGA CAGTGTGCCGAG	1080
35	Glu Asn Ile MET Lys Leu Tyr Gln Arg Ser ---	360
	GGCCATTGCC TGGGAAATCT CAACAGCACC TCATGGGGAA CAGAAGAGGA	1175
40	CCTCGGAAGC CAGGCTTAGC TCTGGACTTC CAGGCCCAGC TTCAGCTCCA	1225
	CAGAGATATT TCCCTCCTTT GATATC	1251
45	EcoRV	

## (2) INFORMATION OF SEQ ID NO:3:

50 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1666

55

# EP 0 737 745 A1

(B) TYPE: nucleic acid

(C) STRANDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

(A) ORGANISMS: G. gallus (chicken)

(D) OTHER INFORMATION: CDS 1-1212

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

-384-TCTTTTGTGTCATCAGTGTA -361
ATAGGAAGAGCACAAAGTCATTTCTTTCTGCCAATCGCCTTGTGACTCCTTCCGTACATA -301
TACACGTGTTGTACAGTATGCTTAAACAGTCCTTGATGAGGTCATCGCTTATTTTGTTC -241
TTTTCTGTGTCATAAGAGTTTGGGTCGCCGGAATTCGCGGCTAGCCTTGGAGAAGCAG -181
CGAGTCTGAACCAGTCCGCCCAGCGCTCCTCCTCCGGCTCACACCTCCTTCCTCCACC -121
GCTCCTCGGAACATCCATCGCTCCGTCGTCATCCGTGCGTCCATCCCGGCTGCGGGGA -61
GCAGCGGAGCGCCCGCTTCGGATCCACGCGGACGGCGGACCCAACCCGGAGAGCAGCG -1
ATG GGT TCC CCC CGC TGG AAG CGT TTC TGC TTC TTG CTC CTC GCA 45
MET Gly Ser Pro Arg Trp Lys Arg Phe Cys Phe Leu Leu Leu Ala 15
GCC TTC ACC TCG TCC CTT CTG CTC TAC GGG CAC TAC TAC GCT ACG 90
Ala Phe Thr Ser Ser Leu Leu Leu Tyr Gly His Tyr Tyr Ala Thr 30
GTG GAC GTG CGC AGC GGC CCG AGG GTC GTG ACC AGC CTG CTG CAG 135
Val Asp Val Arg Ser Gly Pro Arg Val Val Thr Ser Leu Leu Gln 45
CCA GAG CTG CTG TTC CTG GTC CGC CCA GAC ACC CCA CAC CCA GAC 180
Pro Glu Leu Leu Phe Leu Val Arg Pro Asp Thr Pro His Pro Asp 60
AAC AGC CAC CAC AAG GAG CTC AGA GGG ACT GTG AAG AGC AGG GAG 225

```

EP 0 737 745 A1

	Asn Ser His His Lys Glu Leu Arg Gly Thr Val Lys Ser Arg Glu	75
5	TTC TTC TCC CAA CCA TCC TCA GAG CTG GAG AAG CCC AAA CCC AGT	270
	Phe Phe Ser Gln Pro Ser Ser Glu Leu Glu Lys Pro Lys Pro Ser	90
10	GGA AAG CAG CCC ACC CCG TGC CCC CGC TCG GTG GCA GCC ACG GCG	315
	Gly Lys Gln Pro Thr Pro Cys Pro Arg Ser Val Ala Ala Thr Ala	105
15	AAG GCA GAC CCC ACG TTT GGG GAG CTC TTC CAA TTT GAC ATC CCG	360
	Lys Ala Asp Pro Thr Phe Gly Glu Leu Phe Gln Phe Asp Ile Pro	120
20	GTG CTG ATG TGG GAC CAA CAC TTC AAC CCT GAG ACG TGG GAC AGG	405
	Val Leu Met Trp Asp Gln His Phe Asn Pro Glu Thr Trp Asp Arg	135
25	CTG AAG GCA CGA CGC GTC CCA TAC GGC TGG CAG GGT TTG TCC CAA	450
	Leu Lys Ala Arg Arg Val Pro Tyr Gly Trp Gln Gly Leu Ser Gln	150
30	GCA GCT GTC GGC AGC ACC CTG CGT CTC CTT AAC ACC TCC TCC AAC	495
	Ala Ala Val Gly Ser Thr Leu Arg Leu Leu Asn Thr Ser Ser Asn	165
35	ACG CGG CTC TTC GAC CGC CAC CTC TTC CCC GGG GGC TGC ATC CGC	540
	Thr Arg Leu Phe Asp Arg His Leu Phe Pro Gly Gly Cys Ile Arg	180
40	TGT GCC GTG GTG GGC AAT GGG GGA ATC CTC AAC GGC TCA CGG CAG	585
	Cys Ala Val Val Gly Asn Gly Gly Ile Leu Asn Gly Ser Arg Gln	195
45	GGC CGG GCC ATC GAC GCA CAT GAT TTG GTC TTC AGG CTG AAC GGG	630
	Gly Arg Ala Ile Asp Ala His Asp Leu Val Phe Arg Leu Asn Gly	210
50	GCC ATC ACC AAA GGC TTT GAG GAG GAT GTT GGG AGC AAG GTT TCG	675
	Ala Ile Thr Lys Gly Phe Glu Glu Asp Val Gly Ser Lys Val Ser	225
55		

# EP 0 737 745 A1

	TTC TAC GGC TTC ACG GTG AAC ACC ATG AAG AAC TCA CTC ATT GCC	720
5	Phe Tyr Gly Phe Thr Val Asn Thr Met Lys Asn Ser Leu Ile Ala	240
	TAT GAG GCG TAT GGC TTC ACC CGG ACA CCG CAG GGC AAG GAC CTG	765
10	Tyr Glu Ala Tyr Gly Phe Thr Arg Thr Pro Gln Gly Lys Asp Leu	255
	AAG TAC ATC TTC ATC CCC TCG GAC GCA CGC GAC TAC ATC ATG CTG	810
15	Lys Tyr Ile Phe Ile Pro Ser Asp Ala Arg Asp Tyr Ile Met Leu	270
	AGG TCG GCC ATT CAG GGC AGC CCA GTC CCC GAG GGC TTG GAC AAG	855
20	Arg Ser Ala Ile Gln Gly Ser Pro Val Pro Glu Gly Leu Asp Lys	285
	GGC GAC GAG CCA CAG AAG TAT TTT GGA CTG GAG GCA TCT GCG GAG	900
25	Gly Asp Glu Pro Gln Lys Tyr Phe Gly Leu Glu Ala Ser Ala Glu	300
	AAG TTC AAG CTG CTG CAT CCC GAT TTC TTG CAT TAC CTG ACA ACC	945
30	Lys Phe Lys Leu Leu His Pro Asp Phe Leu His Tyr Leu Thr Thr	315
	AGG TTC CTG AGG TCA GAG CTC CTG GAC ATG CAG TAC GGC CAC CTC	990
35	Arg Phe Leu Arg Ser Glu Leu Leu Asp Met Gln Tyr Gly His Leu	330
	TAC ATG CCC AGC ACT GGG GCA CTC ATG CTG CTG ACA GCA CTG CAC	1035
40	Tyr Met Pro Ser Thr Gly Ala Leu Met Leu Leu Thr Ala Leu His	345
	ACC TGC GAC CAG GTC AGT GCC TAC GGG TTC ATC ACA GCC AAC TAC	1080
45	Thr Cys Asp Gln Val Ser Ala Tyr Gly Phe Ile Thr Ala Asn Tyr	360
	GAG CAG TTC TCC GAC CAT TAC TAC GAG CCA GAG AAG AAG CCA CTG	1125
50	Glu Gln Phe Ser Asp His Tyr Tyr Glu Pro Glu Lys Lys Pro Leu	375
55		



# EP 0 737 745 A1

GTG TTC TAC GCC AAC CAC GAC ATG CTG CTG GAA GCA GAG CTG TGG 1170  
 Val Phe Tyr Ala Asn His Asp Met Leu Leu Glu Ala Glu Leu Trp 390  
 5  
 AGG AGT TTG CAC CGG GCG GGG ATC ATG GAG CTG TAC CAG CGG TGA 1215  
 Arg Ser Leu His Arg Ala Gly Ile Met Glu Leu Tyr Gln Arg --- 404  
 10  
 GGGCAGCGCAGTCCCACTGCAAGGACTCTCAATGCAACGCAGAAGCGGTTCTCCTCTTTC 1275  
 CTGAAGGCCTCCTTCTGTCCCTGGAGGGCTCTCCCACACTGGCGGGCCAGCCTGAGGAGC 1335  
 15  
 AGGGCCTGCAGCTGACAGCAGAGCAAAGGTGGTGGTGCAGGGCGAGCCAAGGCTGGCAGG 1395  
 GAAATACTGCAACTCCTCAGGGCCCTTCAGCATCTTATTTGTGACTCTGAGACTGAGCAC 1455  
 20  
 GGCCTTGGGGAGCCTCCGCACGTGGCTGTGAGCTCCTGATGCCATGAGAATGTCTGTGGG 1515  
 GTGGCAGCAGCCCCTGGGAAGCACAGTGTTTCATGTGCAGGTGGGGCACAGTGGTGCTGGA 1575  
 AGGGGATGCTGGAGAAGCATACATCTGACAGACCTCACTTCTTGGAACTTCCTGGAGTTG 1635  
 25  
 CAGCCTCGAAGTCACGCTGGGTAGGCTGCAG 1666

## (2) INFORMATION OF SEQ ID NO:4:

### (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1152
- (B) TYPE: nucleic acid
- (C) STRANDNESS: double
- (D) TOPOLOGY: linear

### (ii) MOLECULE TYPE: DNA

### (vi) ORIGINAL SOURCE:

- (A) ORGANISMS: mouse
- (D) OTHER INFORMATION: 1-1128 sialyltransferase in soluble form

### (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

(-6) TGGCAT -1  
 NdeI

# EP 0 737 745 A1

	ATG GGG AGC GAC TAT GAG GCT CTT ACA TTG CAA GCC AAG GTA TTC	45
5	MET Gly Ser Asp Tyr Glu Ala Leu Thr Leu Gln Ala Lys Val Phe	15
	CAG ATG CCG AAG AGC CAG GAG AAA GTG GCC GTG GGG CCT GCT CCC	90
10	Gln MET Pro Lys Ser Gln Glu Lys Val Ala Val Gly Pro Ala Pro	30
	CAG GCT GTG TTC TCA AAC AGC AAA CAA GAC CCT AAG GAA GGC GTT	135
15	Gln Ala Val Phe Ser Asn Ser Lys Gln Asp Pro Lys Glu Gly Val	45
	CAG ATC CTC AGT TAC CCC AGG GTC ACA GCC AAG GTC AAG CCA CAG	180
20	Gln Ile Leu Ser Tyr Pro Arg Val Thr Ala Lys Val Lys Pro Gln	60
	CCC TCC TTG CAG GTG TGG GAC AAG GAC TCC ACA TAC TCA AAA CTT	225
25	Pro Ser Leu Gln Val Trp Asp Lys Asp Ser Thr Tyr Ser Lys Leu	75
	AAC CCC AGG CTG CTG AAG ATC TGG AGG AAC TAT CTG AAC ATG AAT	270
30	Asn Pro Arg Leu Leu Lys Ile Trp Arg Asn Tyr Leu Asn MET Asn	90
	AAA TAT AAA GTG TCC TAC AAG GGG CCG GGA CCA GGA GTC AGG TTC	315
35	Lys Tyr Lys Val Ser Tyr Lys Gly Pro Gly Pro Gly Val Arg Phe	105
	AGC GTA GAA GGC CTG CGC TGC CAC CTT CGA GAC CAC GTG AAT GTG	360
40	Ser Val Glu Gly Leu Arg Cys His Leu Arg Asp His Val Asn Val	120
	TCT ATG ATA GAG GCC ACA GAT TCT CCC TTC AAC ACC ACT GAA TGG	405
45	Ser MET Ile Glu Ala Thr Asp Ser Pro Phe Asn Thr Thr Glu Trp	135
	GAG GGT TAC CTG CCC AAA GAG ACA TTC AGA ACC AAG GCT GGG CCT	450
50	Glu Gly Tyr Leu Pro Lys Glu Thr Phe Arg Thr Lys Ala Gly Pro	150
55		

EP 0 737 745 A1

	TGC ACA AAG TGT GCC GTC GTG TCT TCT GCA GGA TCT CTG AAG AAC	495
5	Cys Thr Lys Cys Ala Val Val Ser Ser Ala Gly Ser Leu Lys Asn	165
	TCC CAG CTG GGT CGA GAG ATT GAT AAT CAT GAT GCG GTC CTG AGG	540
10	Ser Gln Leu Gly Arg Glu Ile Asp Asn His Asp Ala Val Leu Arg	180
	TTT AAT GGG GCA CCT ACA GAC AAC TTC CAA CAG GAT GTG GGC ACA	585
15	Phe Asn Gly Ala Pro Thr Asp Asn Phe Gln Gln Asp Val Gly Thr	195
	AAA ACT ACC ATC CGC CTA GTG AAC TCT CAG TTA GTC ACC ACA GAA	630
20	Lys Thr Thr Ile Arg Leu Val Asn Ser Gln Leu Val Thr Thr Glu	210
	AAG CGC TTC CTG AAG GAC AGT TTG TAC ACC GAA GGA ATC CTG ATT	675
25	Lys Arg Phe Leu Lys Asp Ser Leu Tyr Thr Glu Gly Ile Leu Ile	225
	CTG TGG GAC CCA TCT GTG TAT CAT GCA GAC ATT CCG CAG TGG TAT	720
30	Leu Trp Asp Pro Ser Val Tyr His Ala Asp Ile Pro Gln Trp Tyr	240
	CAG AAG CCA GAC TAC AAC TTC TTC GAA ACC TAT AAG AGT TAC CGA	765
35	Gln Lys Pro Asp Tyr Asn Phe Phe Glu Thr Tyr Lys Ser Tyr Arg	255
	AGG CTT CAC CCC AGC CAG CCT TTT TAC ATC CTC AAG CCC CAG ATG	810
40	Arg Leu His Pro Ser Gln Pro Phe Tyr Ile Leu Lys Pro Gln MET	270
	CCA TGG GAA CTA TGG GAC ATC ATT CAG GAA ATC TCT CCA GAT CTG	855
45	Pro Trp Glu Leu Trp Asp Ile Ile Gln Glu Ile Ser Pro Asp Leu	285
	ATT CAG CCG AAT CCC CCA TCC TCC GGC ATG CTG GGT ATC ATC ATT	900
50	Ile Gln Pro Asn Pro Pro Ser Ser Gly MET Leu Gly Ile Ile Ile	300
55		

# EP 0 737 745 A1

5      ATG ATG ACG CTG TGT GAC CAA GTT GAT ATT TAC GAG TTC CTC CCA      945  
       MET MET Thr Leu Cys Asp Gln Val Asp Ile Tyr Glu Phe Leu Pro      315  
  
 10     TCC AAG CGC AAG ACA GAT GTG TGC TAC TAT CAC CAG AAG TTC TTT      990  
       Ser Lys Arg Lys Thr Asp Val Cys Tyr Tyr His Gln Lys Phe Phe      330  
  
 15     GAC AGC GCC TGC ACG ATG GGT GCC TAC CAT CCG CTC CTC TTC GAG      1035  
       Asp Ser Ala Cys Thr MET Gly Ala Tyr His Pro Leu Leu Phe Glu      345  
  
 20     AAG AAT ATG GTG AAG CAT CTC AAT GAG GGA ACA GAT GAA GAC ATT      1080  
       Lys Asn MET Val Lys His Leu Asn Glu Gly Thr Asp Glu Asp Ile      360  
  
 25     TAT TTG TTT GGG AAA GCT ACC CTG TCT GGC TTC CGG AAC AAT CGC      1125  
       Tyr Leu Phe Gly Lys Ala Thr Leu Ser Gly Phe Arg Asn Asn Arg      375  
  
 30     TGT TGA GCCAGGGATCCTCAT      1146  
       Cys ---      BamHI      376  
 35

## 40 Claims

1. GalNAc $\alpha$ 2,6-sialyltransferase P-B1 characterized by the amino acid sequence defined by SEQ ID No.1 of the sequence listings.
- 45 2. A GalNAc $\alpha$ 2,6-sialyltransferase P-B1 gene encoding the amino acid sequence of GalNAc $\alpha$ 2,6-sialyltransferase P-B1.
3. The GalNAc $\alpha$ 2,6-sialyltransferase gene according to claim 2 characterized by the nucleotide sequence of from nucleotides 1 to 1698 defined by SEQ ID No.1 of the sequence listings.
- 50 4. GalNAc $\alpha$ 2,6-sialyltransferase P-B3 characterized by the amino acid sequence defined by SEQ ID No.3 of the sequence listings.
- 55 5. A GalNAc $\alpha$ 2,6-sialyltransferase P-B3 gene encoding the amino acid sequence of GalNAc $\alpha$ 2,6-sialyltransferase P-B3.
6. The GalNAc $\alpha$ 2,6-sialyltransferase P-B3 gene according to claim 5 characterized by the nucleotide sequence of from nucleotides 1 to 1212 defined by SEQ ID No.3 of the sequence listings.

7. A recombinant vector comprising a GalNAc $\alpha$ 2,6-sialyltransferase gene encoding the amino acid sequence of the GalNAc $\alpha$ 2,6-sialyltransferase P-B1.
8. The recombinant vector according to claim 7 which is plasmid  $\lambda$ CEB-3034.
9. A recombinant vector comprising a GalNAc $\alpha$ 2,6-sialyltransferase gene encoding the amino acid sequence of the GalNAc $\alpha$ 2,6-sialyltransferase P-B3.
10. The recombinant vector of claim 9 which is plasmid  $\lambda$ CEB3-T20 or plasmid pcDB3ST.
11. A transformant which is being transformed with a recombinant vector comprising a GalNAc $\alpha$ 2,6-sialyltransferase gene encoding the amino acid sequence of the GalNAc $\alpha$ 2,6-sialyltransferase P-B1.
12. A transformant which is being transformed with a recombinant vector comprising a GalNAc $\alpha$ 2,6-sialyltransferase gene encoding the amino acid sequence of the GalNAc $\alpha$ 2,6-sialyltransferase P-B3.
13. An extracellularly releasable protein catalyzing GalNAc $\alpha$ 2,6-sialic acid transfer which comprises a polypeptide portion as being an active domain of the GalNAc $\alpha$ 2,6-sialyltransferase P-B1 or P-B3 together with a signal peptide.
14. The protein according to claim 13, wherein the active domain of the GalNAc $\alpha$ 2,6-sialyltransferase P-B1 is the polypeptide characterized by amino acids of from 233 to 566 defined by SEQ ID No.1 of the sequence listings.
15. The protein according to claim 13 which is the protein SB-690 characterized by the amino acid sequence defined by SEQ ID No.2 of the sequence listings.
16. A gene encoding an extracellularly releasable protein catalyzing GalNAc $\alpha$ 2,6-sialic acid transfer which comprises a polypeptide portion as being an active domain of the GalNAc $\alpha$ 2,6-sialyltransferase P-B1 or P-B3 together with a signal peptide.
17. The gene according to claim 16 characterized by the nucleotide sequence of from nucleotides 1 to 1065 defined by SEQ ID No.2 of the sequence listings.
18. A recombinant vector comprising a gene encoding an extracellularly releasable protein catalyzing GalNAc $\alpha$ 2,6-sialic acid transfer which comprises a polypeptide portion as being an active domain of the GalNAc $\alpha$ 2,6-sialyltransferase P-B1 or P-B3 together with a signal peptide.
19. The recombinant vector according to claim 18 which is plasmid pcDSB-690.
20. A transformant which is being transformed with a recombinant vector comprising a gene encoding an extracellularly releasable protein catalyzing GalNAc $\alpha$ 2,6-sialic acid transfer which comprises a polypeptide portion as being an active domain of the GalNAc $\alpha$ 2,6-sialyltransferase P-B1 or P-B3 together with a signal peptide.
21. A process for preparing an extracellularly releasable protein catalyzing GalNAc $\alpha$ 2,6-sialic acid transfer which comprises a polypeptide portion as being an active domain of the GalNAc $\alpha$ 2,6-sialyltransferase P-B1 or P-B3 together with a signal peptide, which comprises the steps of culturing a transformant which is being transformed with a recombinant vector comprising a gene encoding an extracellularly releasable protein catalyzing GalNAc $\alpha$ 2,6-sialic acid transfer which comprises a polypeptide portion as being an active domain of the GalNAc $\alpha$ 2,6-sialyltransferase P-B1 or P-B3 together with a signal peptide, and recovering said protein from the culture.
22. GalNAc $\alpha$ 2,6-sialyltransferase.
23. GalNAc $\alpha$ 2,6-sialyltransferase derived from mammals.
24. A process for preparing a sialyltransferase which comprises the steps of:
  - (a) expressing a sialyltransferase in a microorganism;
  - (b) extracting the sialyltransferase using 5 to 9 M urea from proteinic aggregate or precipitate that contains the enzyme and is accumulated inside the microorganism;

(c) diluting the extract obtained by the step (b) with a renaturation composition to obtain a primary dilution containing 1 to 4 M urea;

(d) diluting the primary dilution obtained by the step (c) with a renaturation composition to obtain a secondary dilution containing 0.5 to 2 M urea; and

(e) removing urea from the secondary dilution obtained by the step (d) by dialysis to afford a renatured sialyltransferase.

25. The process according to claim 24, wherein the renaturation composition used in the step (c) comprises 1 to 2 M urea, 20 mM MOPS-NaOH, 0.5M NaCl, 20 mM lactose, and 0.5 mM EDTA (pH 7.0); and the renaturation composition used in the step (d) comprises 20 mM MOPS-NaOH, 0.5 M NaCl, 20 mM lactose, and 0.5 mM EDTA (pH 7.0).

26. The process according to claim 24, wherein the sialyltransferase is GalNAc $\alpha$ 2,6-sialyltransferase or Gal $\beta$ 1,4GlcNAc $\alpha$ 2,6-sialyltransferase.

27. A process for preparing a sialyltransferase which comprises the steps of:

(a) expressing a sialyltransferase in a microorganism;

(b) extracting the sialyltransferase using 8 M urea from proteinic aggregate or precipitate that contains the enzyme and is accumulated inside the microorganism;

(c) diluting the extract obtained by the step (b) with a renaturation composition, followed by standing the dilution for at least 12 hours at 4 °C to obtain a primary dilution containing 2 to 3 M urea;

(d) diluting the primary dilution obtained by the step (c) with a renaturation composition, followed by standing the dilution for at least 48 hours to obtain a secondary dilution containing 1 to 2 M urea; and

(e) removing urea from the secondary dilution obtained by the step (d) by dialysis in the presence of one or more divalent cations to afford a renatured sialyltransferase.

28. The process according to claim 27, wherein the renaturation composition used in the step (c) comprises 1 to 2 M urea, 20 mM MOPS-NaOH, 0.5 M NaCl, 20 mM lactose, and 0.5 mM EDTA (pH 7.0); and the renaturation composition used in the step (d) comprises 20 mM MOPS-NaOH, 0.5M NaCl, 20 mM lactose, and 0.5 mM EDTA (pH 7.0).

29. A process according to claim 27, wherein the sialyltransferase is GalNAc $\alpha$ 2,6-sialyltransferase or Gal $\beta$ 1,4GlcNAc $\alpha$ 2,6-sialyltransferase.




Fig. 1




Fig.2



Fig.3




Fig. 4

P - B3 - MG-----SPRWKRCFELLAAFTSSILLXGHYYATVDVRSGRVWTSLLQPELLFVVRPDTPHPDNSHHKELRGTVKSRFFSQPSSELEKPKPSG - 91  
 P - B1 - MGFLIRRLPKDSRIFRWLLLTTFSELIITSESALEFGMEKSI FRQLKIYQSI AHMLQVDTQDQQGSNYSANGRI SKVGLERDI AWLELTAVSTPSGEGKE -100  
 P - B3 - KQTPCPRSVATAKADPTFGE LFQFDIPVLM----- -123  
 P - B1 - EQKKTVPVAKVEAKEKVTVPFPEVMGITTNTTASTASVVERTKEKTTARPVGVGEADGKRTTIALPSMKEDKEKATVPSFGMKVAHANSTSKDKPK -200  
 P - B3 - ----- -123  
 P - B1 - AEPPASVKAIRPVTOAATVTEKKKLRADFKTEPQWDFDDEYILDSSSPVSTCSESVRAKAAKSDWLRDLFLPNITLFDKSYFNVS EWDRL EHFAPPY -300  
 P - B3 - WQHFNPETWDRLKARRVPYGHQGLSQA AVGSTLRLEFDRHLFPGGCIRCAVVGNGGILNGSRQGRAIDAHDIVFRLNGAITKGFEEDVGSKVSFYGFTVN -223  
 P - B1 - GFMEINYSLVEEVM SRLPPNPHQQLLLANSSSNVSTLNTSSNTRLCISCAVVGNGGILNNSGMGQEI DSHDYVFRVSGAVIKGYEKDVGTGTSFYGTAY -400  
 P - B3 - TMKNSLIAEYAGFTRTPQGD LKYIFIPSDARDYIMLSA IQGSPVEG-LDKGDEPQKYFGLEASAEKFKLL-HPDFLHYLTTRFLRSELDMQYGH L -321  
 P - B1 - SLVSSLQNLGHGFKKIPQGHIRYIHFL EAVRDYEWL KALLLDKDIRKGF LNYGRRPRERFDEFTWKNYLVAHPDFLRYLKNRFLKSKNLQKPYWRL -500  
 P - B3 - YMFSTGALMLLTALHTCDQVSAYGFI TANYEQFS DHYYEPEKKPLVFYANHDMLEAEALWRSILHRAGIMELYQR -404  
 P - B1 - YFTTGALLLLTALHLCDRVSAYGYI TEGHQKYS DHYYDKWKRLVFYVNHDFNLEKQVWKRLHDENIMKLYQRS -566

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP94/02182

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> Int. Cl <sup>6</sup> C12N9/10, C12N15/54 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) Int. Cl <sup>6</sup> C12N9/10, C12N15/54 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE, BIOSIS, WPI/WPIL		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
PX	J. Biol. Chem. Vol. 269, No. 29 (1994), Kurosawa Nobuyuki et al. "Cloning and expression of Gal. beta 1, 3 GalNAc-Specific GalNAc alpha 2, 6-sialyltransferase" p. 19048 - 19053	1-29
PX	J. Biol. Chem. Vol. 269, No. 2 (1994), Kurosawa Nobuyuki et al. "Molecular cloning and expression of GalNAc. alpha 2, 6-sialyltransferase" p. 1402-1409	1-29
A	Annu Rev. Biochem. Vol. 50 (1981), p. 733-764	1-29
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "T" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "A" document member of the same patent family		
Date of the actual completion of the international search January 25, 1995 (25. 01. 95)		Date of mailing of the international search report February 14, 1995 (14. 02. 95)
Name and mailing address of the ISA/ Japanese Patent Office Facsimile No.		Authorized officer Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)





DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	GROSS H.J. ET AL.: "Transfer of synthetic sialic acid analogues to N- and O-linked glycoprotein glycans using four different mammalian sialyltransferases" BIOCHEMISTRY, vol. 28, 1989, pages 7386-7392, XP002099388 * the whole document *	22,23	C12N9/10 C12N15/54
X,D	HAMAMOTO T. ET AL.: "Two step single primer mediated polymerase chain reaction. Application to cloning of putative mouse, beta-galactoside alpha 2,6-sialyltransferase cDNA" BIOORGANIC & MEDICINAL CHEMISTRY, vol. 1, no. 2, 1993, pages 141-145, XP002099880 * the whole document *	24-29	
X,D	WEINSTEIN J. ET AL.: "Primary structure of beta-Galactoside alpha 2,6-Sialyltransferase" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 262, no. 36, 25 December 1987, pages 17735-17743, XP002099389 * the whole document *	24-29	TECHNICAL FIELDS SEARCHED (Int.Cl.6) C12N
A	WO 90 12090 A (CHEMBIOMED LTD (CA); MAZID M.A.; KASHEM M.A.) 18 October 1990		
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search THE HAGUE		Date of completion of the search 15 April 1999	Examiner Macchia, G
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

1  
EPO FORM 1503 03 82 (P04C04)

# ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 95 90 3933

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

15-04-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9012090 A	18-10-1990	US 5059535 A	22-10-1991
		AT 92523 T	15-08-1993
		AU 633912 B	11-02-1993
		AU 5528990 A	05-11-1990
		CA 2051374 A,C	13-10-1990
		DE 69002623 T	25-11-1993
		DK 470969 T	03-01-1994
		EP 0470969 A	19-02-1992
		ES 2058908 T	01-11-1994
		JP 5500154 T	21-01-1993
-----			

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82



### CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

### LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

- ☒ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- ☐ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims: 1-3,7,8,11,14,15,17,19 all totally; 13,16,18,20-22, 24-29 all partially.

GalNAc alpha 2,6-sialyltransferase P-B1 or fragment, corresponding gene as in Seq.ID:1/2. Recombinant vector, transformant. Process for preparing said GalNAc alpha 2,6-sialyltransferase.

2. Claims: 4-6,9,10,12 all totally; 13,16,18,20-22, 24-29 all partially.

As invention 1 but concerning GalNAc alpha 2,6-sialyltransferase P-B3 and Seq.ID:3.

3. Claims: 23 totally; 22,24-29 all partially.

GalNAc alpha 2,6-sialyltransferase from mammals and process for its preparation.

4. Claims: 24-29 all partially.

Process for preparing a Gal beta 1,4 GlcNAc alpha 2,6-sialyltransferase.



What is claimed is:

1. GalNAC $\alpha$  2,6-sialyltransferase P-B1 characterized by the amino acid sequence defined by SEQ ID No.1 of the sequence listings.
2. A GalNAC $\alpha$  2,6-sialyltransferase P-B1 gene encoding the amino acid sequence of GalNAC $\alpha$  2,6-sialyltransferase P-B1.
3. The GalNAC $\alpha$  2,6-sialyltransferase gene according to claim 2 characterized by the nucleotide sequence of from nucleotides 1 to 1698 defined by SEQ ID No.1 of the sequence listings.
4. GalNAC $\alpha$  2,6-sialyltransferase P-B3 characterized by the amino acid sequence defined by SEQ ID No.3 of the sequence listings.
5. A GalNAC $\alpha$  2,6-sialyltransferase P-B3 gene encoding the amino acid sequence of GalNAC $\alpha$  2,6-sialyltransferase P-B3.
6. The GalNAC $\alpha$  2,6-sialyltransferase P-B3 gene according to claim 5 characterized by the nucleotide sequence of from nucleotides 1 to 1212 defined by SEQ ID No.3 of the sequence listings.
7. A recombinant vector comprising a GalNAC $\alpha$  2,6-sialyltransferase gene encoding the amino acid sequence of the GalNAC $\alpha$  2,6-sialyltransferase P-B1.
8. The recombinant vector according to claim 7 which is plasmid  $\lambda$  CEB-3034.
9. A recombinant vector comprising a GalNAC $\alpha$  2,6-sialyltransferase gene encoding the amino acid sequence of the GalNAC $\alpha$  2,6-sialyltransferase P-B3.
10. The recombinant vector of claim 9 which is plasmid  $\lambda$  CEB3-T20 or plasmid pcDB3ST.
11. A transformant which is being transformed with a recombinant vector comprising a GalNAC $\alpha$  2,6-sialyltransferase gene encoding the amino acid sequence of the GalNAC $\alpha$  2,6-sialyltransferase P-B1.
12. A transformant which is being transformed with a recombinant

vector comprising a GalNAc $\alpha$  2,6-sialyltransferase gene encoding the amino acid sequence of the GalNAc $\alpha$  2,6-sialyltransferase P-B3.

13. An extracellularly releasable protein catalyzing GalNAc $\alpha$  2,6-sialic acid transfer which comprises a polypeptide portion as being an active domain of the GalNAc $\alpha$  2,6-sialyltransferase P-B1 or P-B3 together with a signal peptide.

14. The protein according to claim 13, wherein the active domain of the GalNAc $\alpha$  2,6-sialyltransferase P-B1 is the polypeptide characterized by amino acids of from 233 to 566 defined by SEQ ID No.1 of the sequence listings.

15. The protein according to claim 13 which is the protein SB-690 characterized by the amino acid sequence defined by SEQ ID No.2 of the sequence listings.

16. A gene encoding an extracellularly releasable protein catalyzing GalNAc $\alpha$  2,6-sialic acid transfer which comprises a polypeptide portion as being an active domain of the GalNAc $\alpha$  2,6-sialyltransferase P-B1 or P-B3 together with a signal peptide.

17. The gene according to claim 16 characterized by the nucleotide sequence of from nucleotides 1 to 1065 defined by SEQ ID No.2 of the sequence listings.

18. A recombinant vector comprising a gene encoding an extracellularly releasable protein catalyzing GalNAc $\alpha$  2,6-sialic acid transfer which comprises a polypeptide portion as being an active domain of the GalNAc $\alpha$  2,6-sialyltransferase P-B1 or P-B3 together with a signal peptide.

19. The recombinant vector according to claim 18 which is plasmid pcDSB-690.

20. A transformant which is being transformed with a recombinant vector comprising a gene encoding an extracellularly releasable protein catalyzing GalNAc $\alpha$  2,6-sialic acid transfer which comprises

a polypeptide portion as being an active domain of the GalNAc $\alpha$  2,6-sialyltransferase P-B1 or P-B3 together with a signal peptide.

21. A process for preparing an extracellularly releasable protein catalyzing GalNAc $\alpha$  2,6-sialic acid transfer which comprises a polypeptide portion as being an active domain of the GalNAc $\alpha$  2,6-sialyltransferase P-B1 or P-B3 together with a signal peptide, which comprises the steps of culturing a transformant which is being transformed with a recombinant vector comprising a gene encoding an extracellularly releasable protein catalyzing GalNAc $\alpha$  2,6-sialic acid transfer which comprises a polypeptide portion as being an active domain of the GalNAc $\alpha$  2,6-sialyltransferase P-B1 or P-B3 together with a signal peptide, and recovering said protein from the culture.

22. GalNAc $\alpha$  2,6-sialyltransferase.

23. GalNAc $\alpha$  2,6-sialyltransferase derived from mammals.

24. A process for preparing a sialyltransferase which comprises the steps of:

- (a) expressing a sialyltransferase in a microorganism;
- (b) extracting the sialyltransferase using 5 to 9 M urea from proteinic aggregate or precipitate that contains the enzyme and is accumulated inside the microorganism;
- (c) diluting the extract obtained by the step (b) with a renaturation composition to obtain a primary dilution containing 1 to 4 M urea;
- (d) diluting the primary dilution obtained by the step (c) with a renaturation composition to obtain a secondary dilution containing 0.5 to 2 M urea; and
- (e) removing urea from the secondary dilution obtained by the step (d) by dialysis to afford a renatured sialyltransferase.

25. The process according to claim 24, wherein the renaturation

composition used in the step (c) comprises 1 to 2 M urea, 20 mM MOPS-NaOH, 0.5M NaCl, 20 mM lactose, and 0.5 mM EDTA (pH 7.0); and the renaturation composition used in the step (d) comprises 20 mM MOPS-NaOH, 0.5 M NaCl, 20 mM lactose, and 0.5 mM EDTA (pH 7.0).

26. The process according to claim 24, wherein the sialyltransferase is GalNAc $\alpha$  2,6-sialyltransferase or Gal $\beta$  1,4GlcNAc $\alpha$  2,6-sialyltransferase.

27. A process for preparing a sialyltransferase which comprises the steps of:

- (a) expressing a sialyltransferase in a microorganism;
- (b) extracting the sialyltransferase using 8 M urea from proteinic aggregate or precipitate that contains the enzyme and is accumulated inside the microorganism;
- (c) diluting the extract obtained by the step (b) with a renaturation composition, followed by standing the dilution for at least 12 hours at 4 °C to obtain a primary dilution containing 2 to 3 M urea;
- (d) diluting the primary dilution obtained by the step (c) with a renaturation composition, followed by standing the dilution for at least 48 hours to obtain a secondary dilution containing 1 to 2 M urea; and
- (e) removing urea from the secondary dilution obtained by the step (d) by dialysis in the presence of one or more divalent cations to afford a renatured sialyltransferase.

28. The process according to claim 27, wherein the renaturation composition used in the step (c) comprises 1 to 2 M urea, 20 mM MOPS-NaOH, 0.5 M NaCl, 20 mM lactose, and 0.5 mM EDTA (pH 7.0); and the renaturation composition used in the step (d) comprises 20 mM MOPS-NaOH, 0.5M NaCl, 20 mM lactose, and 0.5 mM EDTA (pH 7.0).

29. A process according to claim 27, wherein the sialyltransferase

is GalNAc $\alpha$  2,6-sialyltransferase or Gal $\beta$  1,4GlcNAc $\alpha$  2,6-sialyltransferase.



;

;